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 The chemokine CCL20 is thought to be an integral part of the communication between 
the innate and adaptive arms of the immune system, due to expression of the cognate receptor, 
CCR6, on immature dendritic cells and on memory T cells and B cells.   Interest in this particular 
chemokine/chemokine receptor interaction has grown over time and more recently due to roles in 
SIV infection, mucosal immunology, and vaccinology.  The need to further study the 
CCL20/CCR6 interactions is bolstered by our laboratory’s previous findings of increased 
expression of CCL20 in acutely SIV infected lymph nodes and the increased expression of 
CCL20 in response to PAMPs in cells of lymphatic vessels.  This thesis aims to develop and 
improve a system for studying the interaction between CCL20 and CCR6.  I have found that the 
recombinant expression system utilized to obtain macaque chemokines provided highly pure 
fusion proteins.  However, cleavage of the fusion protein into macaque CCL20 has been 
inefficient.  Rhesus macaque CCL20 chemically synthesized using regioselective cyclization was 
highly biologically active using the chemotaxis assay and stable cell lines expressing CCR6.  
Chemotactic inhibition studies identified five compounds that inhibited CCL20-induced 
chemotaxis.   The surfactant, GML, did not inhibit CCL20-induced migration.  The anti-
inflammatory botanicals, EGCG and gallotannin, both inhibited CCL20-driven migration at high 
concentrations. The three CCR6 extracellular loop mimetic peptides also partially inhibited 
CCL20-induced migration at high concentrations.  In conclusion, I have utilized both a 
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recombinant protein expression system and regioselective cyclization peptide synthesis to obtain 
bioactive, nonhuman primate chemokines.  I have also successfully developed an in vitro system 
to study CCL20-induced migration, and have identified a number of botanical and biochemical 
elements that inhibit CCL20-induced migration.  The public health significance of this study is 
related to the fact that vaccine efficacy may be affected by anti-inflammatory compounds that 
inhibit CCL20-mediated chemotaxis.  Another way in which public health could be affected by 
this study is in using the anti-inflammatory compounds studied to treat chronic inflammatory 
conditions in which the pathology of the disease is related to up-regulation of CCL20 and CCR6. 
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1.0  Introduction 
The complexity of the immune system provides the body with a method to fight pathogen 
associated challenges.  The immune response to inflammation caused by the invading pathogens 
develops as infected or injured cells in the local environment produce signals to aid the local 
entry of specialized immune cells.  A gradient of small proteins, or chemokines, drives the 
homing of the immune cells. 
1.1 Chemokines and Chemokine Receptors  
Chemokines are small, structurally related chemo-attractant cytokines, in the size range 
of 8-10kDa, that are involved in a wide range of biological functions, from hematopoeisis to 
organogenesis3, 43.  The expression of some chemokines is required to direct the architecture of 
developing lymphoid tissue42, 43.   A third functional activity of chemokines is to aid in the 
activation of a specific adaptive response, either a TH1 or TH2 immune response45, 46, 47.  
Chemokine biology is important in immunology and infectious disease in that in some 
pathogenic viral and bacterial infections, as well as cancers and autoimmune diseases, dys-
regulation of chemokines and expression of chemokine receptors can contribute to the 
pathogenesis of the disease9, 16, 44. One of the main functions of chemokines is to induce the 
trafficking of leukocytes into sites of inflammation3, 12.   
Chemokines are defined and functionally grouped in at least two ways.  First they are 
classified by the sequence of the amino acids near the amino-terminus of the protein, i.e. by the 
proximity and location of the amino-terminal conserved cysteines that form the disulfide bridges 
in the protein, specifically they are CC, CXC, CX3Cand XC chemokines12, 13. The conserved 
cysteines of CC chemokines are directly next to each other.  The cysteines of CXC and CX3C 
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chemokines have as the name implies some other amino acid present in the sequence before the 
next conserved cysteine.  XC chemokines have only one conserved cysteine in the amino-
terminal region of the protein sequence12, 13.  
Chemokines are also defined functionally by their expression profile as present during 
either homeostasis or inflammation3, 12.  Homeostatic chemokines are expressed under normal 
physiological conditions and aid in the development of secondary microstructures within 
lymphoid tissue19, 42, 43.  For example, CCL21 is a homeostatic chemokine that is highly 
expressed in the paracortical region of peripheral lymph nodes41, 45.  This expression aids in the 
cross talk, maturation, and antigen education of naïve T cells and mature dendritic cells (DCs) 
which both express the receptor, CCR741, 42, 56, 57.  Another homeostatic chemokine CXCL13 is 
expressed mainly in the germinal centers of lymph nodes, aiding in the development and 
maturation of B cells41.  An additional function of a homeostatic chemokine is to draw immature 
dendritic cells (DCs) into the tissue, so that these local DCs can continually sample the local 
environment and be poised to respond to pathogen-associated inflammation44, 47.   
Inflammatory chemokines are up-regulated via the NFκB pathway during pathogen 
challenge, in response to increased IFNγ expression9, 44.  The chemokine CXCL10 is a prime 
example of an inflammatory chemokine, due to findings that upon SIV infection, as IFNγ goes 
up, this chemokine is also highly expressed6, 44.      
1.1.1 Chemokine CCL20: Expression and Other Properties 
The chemokine CCL20 or MIP-3α, (macrophage inflammatory protein) is a CC 
chemokine13, with unique properties in that in some local tissue environments CCL20 is thought 
to have properties of both the homeostatic and inflammatory chemokines19.  As expected for 
other inflammatory chemokines, CCL20 is secreted by macrophages in response to inflammation 
 3 
and has been shown to be under the control of the NFκB inflammation response pathway26, 32.  In 
the skin, epithelial cells secrete CCL20 at low constitutive levels under normal conditions; on the 
other hand, with a pathogen challenge or chronic inflammation as in atopic dermatitis, CCL20 is 
up-regulated32.  Additionally, the expression of CCL20 in the skin has been related to the 
homeostatic influx and maintenance of Langerhan cell (LC) precursors56, 57.  Both properties of 
homeostatic and inflammatory expression have been shown in the gut, where the follicular 
associated epithelial dome in Peyer’s patches constitutively expresses CCL2033, 34.  The 
importance of a homeostatic interaction of CCL20 with its receptor, CCR6, in the development 
of gut-associated lymph tissue (GALT) is indicated by the fact that CCR6-/- mice have reduced 
numbers and cellularity of Peyers’ patches36.  CCL20 is also up-regulated due to inflammation in 
the gut, as in SIV infection6, or to chronic inflammation as in inflammatory bowel disorder or 
Crohns’ disease27.  In the peripheral lymph node, CCL20 is shown to be an inflammatory 
chemokine, where the constitutive level of CCL20 expression is increased during acute SIV 
infection6.  Another indicator of the inflammatory properties of CCL20 is that lymphatic 
endothelial cells increase CCL20 expression with IL-1β or LPS treatment via TLR signaling62.  
In the female genital tract, there is evidence of both homeostatic and inflammatory chemokine 
properties2, 7.  Recent vaccine adjuvant studies of the female genital tract define a successful 
adjuvant or immunogen by increases in CCL20 expression7.  For the above reasons, immune 
function of CCL20 is unique depending on the local tissue environment. 
1.1.2 Chemokine Receptor CCR6: Expression and Other Properties 
 The receptor for CCL20 is CCR6 19.  Adaptive immune cells including memory T cells, 
mononuclear cells, B cells, and immature dendritic cells (DCs) express CCR6 32.  CCL20 and 
CCR6 are thought to be integral parts of the communication between the innate and adaptive 
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arms of the immune system because of the expression of CCR6 on immature DCs and memory T 
cells19, 37.  Local response to inflammation up-regulates CCL20 expression56.  This and other 
signals bring the immature DCs towards the focus of increased CCL20 expression where they 
become mature and activated, following antigen uptake and processing 56.  DCs mature losing 
some level of CCR6 expression and gaining CCR7 expression, which drives the mature DCs to 
home to the lymph node where they interact with naïve T cells3.  Memory T cells may migrate 
into the inflamed environment via some of the same signals, and as the DC mature and present 
antigen to the memory T cells, they can begin to display effector immunological properties and 
contribute to resolution of the pathogen challenge and local inflammation28.   
1.1.3 HIV and CCL20 / CCR6   
The most recognized chemokine receptors in SIV or HIV immunology are CCR5 and 
CXCR4, which are used by gp120 protein for viral entry into CD4 positive cells38, 39.  One 
commonly studied aspect of HIV immunology is the reduction of immune cells associated with 
the gut-associated lymphoid tissue (GALT) during acute infection15, 20.  It has been shown that 
the CD4 T cells in the GALT are targeted by virus infection and these numbers do not rebound to 
the original percentages even with HAART treatment20, 21.  The chemokine/chemokine receptor 
pair of CCL20 and CCR6 become important considerations during SIV or HIV infection for a 
few reasons.  One reason is the CCL20/CCR6 pair are thought to be influential in regulating 
immune responses in both regions affected by sexual transmission of HIV, the vagina and the 
gut, where the primary immune response is mounted15, 20, 21, 50.  Another reason is that DCs 
(which express CCR6 and respond to CCL20) have been shown to be some of the first targets of 
HIV replication, in addition to serving as ‘trojan horses’ for virus dissemination21, 48.    
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CCL20 has been shown to be up-regulated in both the gut (colon) and lymph node during 
acute SIV infection6.  This up-regulation is congruent during other lentiviral infections such as 
by human T-cell leukemia virus type 1 (HTLV) where there is up-regulation of CCL20 
expression9.  Further indication of a dysfunctional relationship of CCL20 and HIV is that HIV 
proteins reduce chemotaxis of B cells to CCL20, which are a cell type that expresses CCR61.  
Ghosh, et al, further identifies anti-HIV properties of CCL20 where CCL20 directly inhibited 
HIV replication55.  In the female macaque vagina, treatment with GML (glycerol monolaurate), a 
biochemical surfactant, inhibited SIV replication10.  Reported in the same study, CCL20 
expression in the vagina was increased with SIV infection and that upon observing inhibition of 
SIV replication with GML treatment, CCL20 expression was reduced as well 10.  Finally, another 
CCR6 mediated anti-HIV activity was observed by Lafferty, et al49.  The authors found that 
signaling through the CCR6 receptor up-regulated the expression of a naturally occurring anti-
HIV molecule, APOBEC3G49.   
CCR6 and CCL20 are associated with mucosal tissue, both the female genital tract and 
gut lymphoid tissue, including Peyers patches59, 28, 33, 35.   Although the pathways and functional 
roles have not been well developed yet, there may be great importance to the CCR6/CCL20 
interaction early during HIV infection.  It may be that upon sexual transmission, the epithelial 
layers of the female genital tract or anal/rectal junction is damaged.  This epithelial damage, as 
well as virus-infected cells, free virus and other proteins and factors present in mucus or 
ejaculate perpetuates a local inflammatory response, and the down-stream up-regulation of 
CCL20.  The increased  levels of CCL20 as well as other inflammatory cytokines and adhesion 
signals increase the number of immature DCs brought into the environment, which can serve as 
‘trojan horses’ for virus dissemination or as target cells21, 48.  While primary up-regulation of 
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CCL20 is likely not the only answer to HIV immune evasion and persistence, there is a 
substantial body of evidence suggesting that consideration of the CCR6/CCL20 interactions 
during SIV/HIV may be lucrative in developing successful HIV vaccines or therapeutics.   
Models that will improve our understanding of the CCR6 and CCL20 pathways and 
interactions in health and disease, including macaque models, need to be developed and 
improved.  Since most reagents commercially available are of human specificity, an efficient 
protocol for expression and purification of non-human primate chemokines must be developed to 
accommodate future studies.  In particular, there are few if any reagents for the study of 
nonhuman primate chemokines, including CCL20.  Therefore, the primary goal of these studies 
was to generate macaque CCL20 and develop a system to characterize of the CCR6: CCL20 
interaction.    
1.2 Recombinant Protein Purification  
Recombinant DNA technology has developed exponentially as the use of genes and 
proteins in vaccines and therapeutics has developed with modern medicine. Recombinant protein 
expression is a method for obtaining large quantities of protein that has long been utilized 
commercially75, 83.  The systems that have been used are both eukaryotic and prokaryotic, viral 
vector or plasmid based systems each having advantages and disadvantages in the production, 
yield and safety of the desired product75, 83.   
One of the first prokaryotic systems used to produce commercial recombinant proteins is 
the gram-negative bacteria E. coli75.  Advantages to expression in E. coli are that cultures are 
grown easily to a high density in simple nutrition media and that a large body of knowledge 
about recombinant expression in E. coli has been gathered to enhance production of proteins75.  
In genetically un-manipulated E. coli, the reduced state of the cytosol inhibits di-sulfide bond 
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formation and endogenous enzymes rarely mark the protein for proteolysis75.  Other protein 
modifications, such as glycosylation, do not occur in E. coli75.   
Recombinant protein expression in E. coli has been manipulated by knowledge of 
bacterial cellular metabolism pathways and antibiotic resistant plasmids to enhance protein 
production75.  Plasmids are mutated to contain antibiotic resistance, a strong promoter, and the 
lacz gene linked to the recombinant gene83.  A relatively universal manipulation utilizing these 
factors is that cells that have taken up plasmids encoding antibiotic resistance genes also acquire 
the control of the T7 promoter and the lacz gene and the recombinant protein is expressed upon 
the addition of IPTG (isopropyl β-D-1-thiogalactopyranoside)75, 83.  Other manipulations of 
recombinant protein expression in E. coli include transforming the cells with plasmids encoding 
genes that enhance production of a certain type of protein.  In the end, based on the type of 
recombinant protein desired, a wide variety of E. coli competent cells are available and are 
chosen based on the protein translational properties that will ease the production of the 
recombinant protein.  
1.2.1 Origami B DE3 and Rosettagami B DE3  
The strains of E. coli utilized in the expression and purification protocol here are the 
Origami B DE3 and Rosettagami B DE3 (Invitrogen) cells, based on properties that would 
enhance the production of a recombinant non-human primate chemokine.  Both strains are 
derived from a mutant cell line, DE3 lysogens, that express protein in response to IPTG under 
the control of T7 promoter and lacz metabolic pathway.  They both also express mutant plasmids 
that allow for the formation of disulfide bonds in the cytosol of the E. coli and more efficient 
protein refolding in vivo72.   
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Recombinant mammalian protein expression in E. coli is made more difficult by the 
rarity of certain tRNAs in E. coli5.  Low expression of tRNAs that complement the codon push 
the cell to mis-incorporate an amino acid and therefore potentially change the structure and 
function of the resultant recombinant protein5.  To combat this problem, in addition to the other 
plasmids contained in the Origami B DE3 cell, Rosettagami B DE3 cells encode the rare tRNAs 
that are lacking in the E. coli but are necessary for proper mammalian translation of protein5.  In  
conclusion, we used strains of E. coli that were purported to enhance the expression of our 
desired recombinant proteins, chemokines.   
1.2.2 SUMO Fusion Protein Expression  
A proper protein expression technology is also used to express recombinant proteins of 
interest.  The SUMO (Small Ubiquitin-Like Modifier) plasmid expression system (Life Sensors) 
provides specificity during purification of the recombinant proteins, as both the fusion protein 
and the protease contain 6-X-His tags allowing purification of these elements, simply and to a 
high degree, by metal affinity column purification.  Another advantage of the SUMO expression 
system is that the exact n-terminal residue of the recombinant protein can be defined (Life 
Sensors).  The SUMO protease is highly specific in that the tertiary structure of the fusion 
protein is the only substrate for the enzyme cleavage reaction70, 71, 79.  In most cases, specificity 
of cleavage results in un-altered recombinant protein, in this study, rhesus macaque CCL20.  
1.3 Peptide Synthesis 
Peptides can be synthesized using organic chemistry protocols, but it is a more expensive 
biochemical technique used to obtain large quantities of small proteins81, 82.  There are two major 
methods by which peptides are synthesized by coupling the N-terminus of an amino acid to the 
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C-terminus of another, beginning with the C-terminal amino acid in the peptide and ending at the 
n-terminal residue82.   
Liquid phase peptide synthesis is the classical method for chemically producing 
peptides81.  The other method for synthesizing peptides is called solid phase synthesis, where the 
c-terminal amino acid is bound to insoluble beads or resin82.  The side chains of the amino acid 
can be protected by tboc (using trifluoroacetic acid) or fmoc (using 9-fluorenylmethylcarbonyl) 
chemistry81, 82.   The difference between each is that upon building the peptide either a neutral 
(tboc) or positively charged amine group (fmoc) is exposed to the next amino acids c-terminus82.  
For the synthesis of our rhesus macaque CCL20, regioselective cyclization was used.  By this 
solid phase peptide synthesis, sulfides are protected from disulfide bond formation which occurs 
regularly in protein synthesis by thiol protecting groups81, 82.  Additionally, in this type of 
synthesis, as the amino acid chain is synthesized, sulfides can be revealed (or de-protected) and 
the disulfide bond formation can be directed82.   
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2.0  Statement of the Problem 
Understanding the contribution of chemokines and their receptors to the complexity of 
the immune system is important to modeling the progression of immunologic and infectious 
diseases.  CCL20 is constitutively and over expressed during homeostatic and inflammatory 
conditions, respectively.  The cognate receptor CCR6 is unique in that it is one of few non-
promiscuous chemokine receptors12.  The only other known ligands for CCR6 are a family of 
host anti-microbial peptides, the β-defensins8, 32.  Inflammatory expression and response to 
CCL20 may provide a link between the innate and adaptive immune systems.  Response of 
immature dendritic cells to CCL20 via CCR6 signaling makes study of CCL20 as a vaccine 
adjuvant a likely course.  Expression of CCL20 (vagina2, 7, 10, 59, likely the anal/rectal junction, 
colon19, and GALT19 ) in tissue compartments exposed to or serve as primary sites of virus 
dissemination  HIV during sexual transmission also lends credence to study of CCR6/CCL20 in 
HIV vaccines and mucosal immunity.  We have shown that CCL20 is expressed by lymphatic 
endothelial cells at the afferent face of LNs and this is upregulated during the early phase of SIV 
infection48, 62.  The recently revealed anti-HIV activity of CCL20 and intracellular ligand-driven 
signaling through CCR6 provides additional evidence that the CCR6/CCL20 interaction is 
important in understanding innate immune properties that combat HIV infection49, 55.   These 
findings have provided impetus for study of this chemokine/chemokine receptor interaction in 
vaccine adjuvant studies, mucosal immunology and HIV or SIV infection.  The overall 
objective of this study was to develop a robust and improved system for studying the 
interaction between CCL20 and CCR6 using both recombinant and chemically synthesized 
nonhuman primate chemokines.  In this study, generating macaque CCL20 provides a method 
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to study the efficacy of using CCL20 as a vaccine adjuvant in future studies.  Identification of 
inhibitory compounds of CCL20-mediated chemotaxis may provide possible treatments for 
chronic inflammatory diseases to which some of the disease pathology is associated with up-
regulated CCL20 expression (atopic dermatitis32, Crohn’s disease27, etc.).     
2.1 Specific Aim 1: To Develop a System to Generate Rhesus Macaque CCL20 
Expression of chemokines in E. coli is a well-established method for obtaining large 
quantities of recombinant proteins.  However, there are few, if any, commercially available 
macaque chemokines for in vitro and in vivo studies of monkey models of immunology and 
disease.  Recombinant expression of proteins can be a flexible and cost effective way to obtain a 
wide variety of molecules in large quantities.  In addition, such a strategy readily allows 
mutagenesis as a relatively simple way to obtain different forms of proteins for study.   
Chemical synthesis of peptides is an alternative method for obtaining highly pure proteins 
for experimental application.  Additionally, regioselectively cyclized peptide synthesis can 
provide a method to produce highly pure proteins with directed di-sulfide bonding, which is 
thought to be required for proper tertiary structure formation of chemokines and which could 
contribute to more robust bioactivity of the resultant molecule.  I have established systems 
whereby non-human primate chemokines were obtained by recombinant expression and whereby 
chemically synthesized non-human primate chemokines were found to be bioactive.   
2.2 Specific Aim 2: To Develop and Apply a Functional Assay for Testing the 
Bioactivity of Recombinant and Synthetic Macaque CCL20 
 The importance of studying the interaction between CCL20 and CCR6 is defined by 
vaccine adjuvant studies, DC biology, and mucosal immunology.  Due to the expression of 
multiple chemokine receptors on most cell types, studying specific chemokine and chemokine 
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receptor interaction is difficult with primary cells.  A robust functional assay is important for 
studying the activity any specific chemokine.  Therefore, I established a robust chemotaxis assay 
with the L1.2 murine pre-B cell line transfected both transiently and stably to express human 
CCR6.  These stable CCR6 cells allowed me to examine specifically the outcomes of some 
CCL20 and CCR6 interactions.   
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3.0  Materials and Methods 
3.1 Generation of rhesus macaque chemokine 
To utilize recombinant protein expression for producing a macaque chemokine, the E. 
coli strains Origami B DE3 and Rosettagami B DE3 cells (Invitrogen) were transformed with 
one µl ampicillin (amp) resistant plasmid, p.SUMO.rh.CCL20 plasmid (Basu, et al84, YT/TAR 
2006).  After heat shock (100°C in a water bath) the cells were rested on ice for 5 minutes.  The 
cells were incubated for one hour at 37°C with vigorous shaking.  Positive transformants were 
selected by plating transformations on LB (Luria Bertani) / amp (100µg/ml) plates containing 
kanamycin (15µg/ml) and tetracycline (12.5µg/ml) for Origami B DE3 and kanamycin, 
tetracycline, and chloramphenicol (34µg/ml) for Rosettagami B DE3. Plates were incubated for 
24-36 hours at 37°C.  A seed culture was prepared by inoculating one colony into 12-200 ml of 
LB media supplemented with the appropriate drugs or antibiotics for each E. coli strain as 
described above and grown overnight at 37°C with vigorous shaking.  The seed culture was then 
added at a 1:10 dilution to 1L pre-warmed LB media supplemented with the appropriate drug or 
antibiotics and cultured until the optical density of the culture reached an A600 of 0.4.  IPTG 
(isopropyl β-D-1-thiogalactopyranoside) was then added to the culture to a final concentration of 
200µM to induce protein expression and the cells were further cultured at 37°C with vigorous 
shaking for 3 hours.   
To isolate the induced SUMO-CCL20 fusion protein from the culture of bacteria, the 
culture was lysed with 15 ml Bugbuster protein extraction reagent (Novagen) supplemented with 
15µl Benzonase (Novagen), and 67µg/ml PMSF (phenyl methyl sulphonyl fluoride).  The lysate 
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was pelleted to separate soluble and insoluble material.  The insoluble inclusion bodies were 
solubilized to release aggregated SUMO-CCL20 fusion protein in 50mM HEPES-NaOH pH7.5, 
6M guanidine HCl, 25mM DTT (diothiothreitol).  The SUMO-CCL20 fusion protein was 
purified by metal affinity column binding with TALON spin columns (Clontech), according to 
the manufacturer’s recommendations.   
To prepare the SUMO-CCL20 fusion protein for cleavage and the recombinant CCL20 
protein for HPLC purification, the sample was randomly refolded at a ratio of one to five 
volumes with refolding buffer containing 50mM HEPES pH7.5, 200mM NaCl, 1mM DTT, 1M 
NDSB201 (3-(1-Pyridino)-1-propane sulfonate).  NDSB201 acts to facilitate the renaturation of 
proteins in addition to preventing protein aggregation.  The refolded SUMO fusion protein 
preparation was concentrated and further purified by size by centrifugation in the Amicon Ultra-
4 30kDa cut-off centrifugal filter device (Millipore, # UFC803024).  The purified fusion protein 
preparation was then dialyzed to remove high concentrations of chelating and reducing agents by 
overnight dialysis in 1L 50mM Tris-HCl, 500mM NaCl.  The dialyzed SUMO fusion protein 
preparation was subsequently cleaved of the SUMO fusion tag by addition of SUMO protease 
(Life Sensors) and incubation at 37°C for from one up to three hours or overnight.  Both the 
SUMO fusion protein and SUMO protease were purified from the cleavage reaction by metal 
affinity column binding by the same method as above (Talon Spin columns [Clontech]).  At least 
1mg of the SUMO-CCL20 fusion protein was sent for HPLC purification.   
To examine the CCL20 product throughout the expression and purification steps the 
bacterial culture and protein preparations were sampled after performing different steps of 
expression and were analyzed by SDS-PAGE and immunoblotting.  All samples were prepared 
for SDS-PAGE analysis by boiling for 5 minutes with an equal volume of 2X SDS-PAGE buffer.  
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Samples were then separated on 12 or 15% resolving polyacrylamide gels by electrophoresis at 
85V for 30 minutes at 4ºC followed by 125V for 1 hour at 4ºC.  For Coomassie brilliant blue 
staining, gels were then fixed with 10% acetic acid / 25% isopropanol with shaking for 15 
minutes at room temperature, stained with shaking with 0.25% Coomassie blue stain overnight at 
room temperature, de-stained with 5% methanol / 7.5% acetic acid, and subsequently dried 
encased in cellulose for analysis.   Immunoblotting was performed by transferring proteins to 
PVDF membranes and use of the Pierce Fast Western Blot Kit (Pierce, cat 35050).  PVDF 
membrane was wetted in 100% methanol for 15 sec, then in water for 2 minutes, and finally 
equilibrated in Tris / Glycine transfer buffer until use.  The polyacrylamide gel was also 
equilibrated in transfer buffer for 15 minutes.  A gel sandwich was prepared with fiber pads, 
filter paper, PVDF membrane and polyacrylamide gel, all soaked in transfer buffer.  A wet 
transfer was performed with the Bio-Rad Mini-Protean Cell II transfer apparatus at 4ºC for one 
hour at 100V 350mA. The membrane was then dried for two hours at RT, and subsequently 
blocked in 2% milk for 30 minutes with shaking at RT.  Either anti-CCL20 (human, R&D 
Systems, AF360 or rhesus, ProSci, PAS 13809) or anti-HIS (RGS•His HRP conjugate (Qiagen, 
34450) antibodies were diluted to the manufacturers’ suggested concentrations in Pierce Fast 
Western Blot antibody diluent.  As required, a secondary antibody (mouse anti-goat, Rockland, 
Inc., 105-3102) was utilized to detect the anti-CCL20 staining.  The membrane was washed five 
times and subsequently incubated with detection reagent, then exposed to film for 30 seconds.  
The film was then developed and analyzed.  
Peptide synthesis using regioselective cyclization was performed by providing the 
University of Pittsburgh Peptide Facility with rhesus macaque CCL20 sequence (70 amino acids, 
mature form).  Two milligrams (lyophilized) of a test batch was received for biological activity 
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testing.  The protein was resuspended in nuclease free water and quantified by BCA protein 
assay (Pierce, cat# 23227).  After biological activity was confirmed via a chemotaxis assay, the 
peptide facility continued with HPLC purification of the remaining batch (35 milligrams).  Pure 
(99%) lyophilized rhesus macaque CCL20 was resuspended in nuclease free water, quantitated 
by BCA protein assay and used in the functional assays of this study.   
3.2 Application of chemotaxis functional assay for in vitro system development  
To develop a functional assay to analyze CCL20-mediated chemotaxis, transient 
transfections were performed following methods developed by Fox et al.  L1.2 murine pre-B 
cells were transfected by electroporation (300V, 975µF, Bio-Rad Gene Pulser II) with plasmid 
encoding the human CCR6 receptor (pcDNA3.1 human CCR6 from UMR cDNA resource 
center).  Transfected cells were cultured in L1.2 media (Hepes modified RPMI (Sigma), 10% 
FBS, 1mM non-essential amino acids, L-glutamine, penicillin/streptomycin, sodium pyruvate 
and 0.5mM β-mercaptoethanol) overnight in the presence of 5mM sodium butyrate.   
To perform chemotaxis, cells were prepared for chemotaxis by centrifugation and 
resuspension in chemotaxis media (0.1% BSA RPMI).  Concentrations (1nM-1µM) of 
synthesized regioselectively cyclized rhesus (University of Pittsburgh Peptide Facility) and 
commercial human CCL20 (Peprotech) were diluted in chemotaxis media.  The bottom reservoir 
of chemotaxis plates (Neuroprobe, 5um pore size) were blocked against non-specific chemokine 
adherence with 1% BSA RPMI for 30 minutes at room temperature.  The chemokine dilutions 
were then loaded in the aspirated wells and the membrane placed over the plate.  Cells (20ul) 
were loaded on to the membrane at 200,000 cells/20ul volume.  The plate was incubated at 
37°C/5%CO2 for 3 hours.  After incubation, the plate was scraped to remove cells off the top of 
the membrane and cells that had migrated to the lower wells of the chemotaxis were counted on 
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a hemocytometer.  Data analyses of chemotactic migration were performed using GraphPad 
Prism software (GraphPad Software, Inc., San Diego, CA).     
To generate stable cell lines for continued CCL20-mediated chemotaxis analyses, 
transfected L1.2 cells were selected  in geneticin supplemented L1.2 media to develop stable cell 
lines to study subsequent preparations of macaque CCL20.  A separate culture of transiently 
transfected cells was grown in L1.2 media overnight.  Cultures were centrifuged and 
resuspended in L1.2 media supplemented with 1mg/ml of geneticin (Gibco) at a cell 
concentration of 20,000/150ul.  Cells were plated in 96 well plates and cultured until foci of 
growing cells were evident in multiple wells.  Wells with cells growing were chosen randomly 
and expanded in geneticin supplemented L1.2 media.  Primary clones were moved forward based 
upon their migration to the optimal concentration of synthetic rhesus CCL20 (10nM).  Secondary 
clones were selected from cultures that migrated potently to chemokine were cloned by diluting 
the culture to one cell/450ul in geneticin supplemented L1.2 media.  Wells with cells growing 
were expanded, chemotactic ability was confirmed, and 12 stable cell clones were saved for 
further CCL20-mediated chemotaxis analysis.   
To characterize and correlate receptor expression with functional chemotactic ability on 
both the transiently transfected and the stable cell line, flow cytometry was performed on 
parental, transiently transfected and stable CCR6 expressing cell clones.  Cells that had been 
prepared for chemotaxis were washed and stained in blocking buffer (1X PBS with 2% 
BSA/200µM sodium azide) with PE-labeled anti-human CCR6 antibody (BD Biosciences, 
(Clone 11A9, 551773)) at 4°C for 30 minutes.  Samples were washed and fixed by resuspension 
in 0.25% paraformaldehyde/block buffer.  Data were acquired on a BD Canto using FACS Diva 
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Software.  Data were subsequently analyzed with FlowJo software (Tree Star, Inc., Ashland, 
OR).      
 To examine the cell populations that express CCR6 in blood, primary rhesus macaque 
PBMCs were stained with antibodies PBMCs were then stained with a 6 color panel (BD 
Biosciences, Anti-CD3 Pe-Cy7 (Clone SP34.2, 557749), Anti-CD4 PerCP (Clone L200, 
550631), Anti-CD20 FITC (Clone 2H7, 556632), Anti-CCR6 PE (Clone 11A9 551773), Anti-
CD8 APC-Cy7 (Clone RPA-T8, 557760) and Anti-CD69 APC (Clone FN50, 555533).  Data was 
aqcuired on the BD Canto, and analyzed with Flow Jo software (Tree Star, Inc., Ashland, OR).    
To analyze the effect of botanicals, receptor peptide mimetics, and the biochemical 
surfactant on CCL20-mediated chemotaxis, chemotaxis was performed with stable CCR6 cell 
clones in the presence of the candidate inhibitors.  To identify the effect of the botanicals or 
receptor peptide mimetic on CCL20-mediated chemotaxis, 10nM rhesus CCL20 was diluted with 
increasing concentrations of each.  Migration towards the optimal concentration of synthetic 
rhesus CCL20 was considered the control for chemotactic activity, percent migration was 
calculated by dividing samples containing the botanicals or receptor peptide mimetic by the 
positive control (10nM synthetic rhesus CCL20) and setting the migration towards 10nM 
synthetic rhesus CCL20 at 100%.  Three R6-ECL2s (described in Figure 15) were synthesized 
by the University of Pittsburgh Peptide facility. All R6-ECL2s were resuspended in nuclease free 
water and quantitated by BCA protein assay. A titration of one nM to one µM of each R6-ECL2 
was added to 10nM rhesus CCL20.  EGCG (Sigma-Aldrich, catalog #E4143) and gallotannin 
(Sigma-Aldrich, catalog #403040) were also water-soluble and treated in the same way as the 
R6-ECL2s.  Glycerol monolaurate or Monomuls 90-L 12 (Code 56150COG, batch GR72954301, 
Cognis corporation, Cincinatti, OH) was not water-soluble and was resuspended in 100% ethanol 
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at 10 mg/ml.  The final concentration of ethanol was 0.025% in the 50µg/ml preparation.  All 
samples were normalized to 0.025% ethanol to negate any inhibitory effects that may have been 
attributed to ethanol.  Chemokine (10nM) or cells were mixed with varying concentrations of 
GML and at lower concentrations, ethanol was also added to control for ethanol in every sample.    
Statistical analysis was performed by the paired t-test.  Values of * p<0.05, ** p<0.01, 
*** p<0.001 were found to be significant.     
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4.0  Results: Recombinant Protein Expression 
4.1 Expression and purification of a SUMO-CCL20 fusion protein.   
To identify and analyze the sequence differences between human and rhesus macaque 
CCL20, p.SUMO.rh.CCL20 was sent to the University of Pittsburgh Sequencing Facility after 
isolation of the plasmid using the Wizard Plus Miniprep Kit (Promega).  Both the reference 
human CCL20 (NM 004591) and the rhesus macaque CCL20 nucleotide sequence were 
translated using Vector NTI software.  Rhesus macaque CCL20 protein shared 85% identity to 
the human CCL20 protein (Figure 1A).  To analyze the location of the differences in amino acid 
as it related to the structure of the protein, human CCL20 protein sequence was analyzed with 
Cn3d software.  Secondary protein structures of an α-helix are marked by a green cylinder and 
β-sheets are marked by a gold bar (Figure 1C).  The amino acid differences in the rhesus 
sequence as compared to the human sequence are marked in yellow (Figure 1C).  Analysis of the 
location of the differences in the rhesus CCL20 revealed that changes occurred over the entire 
sequence of the protein (Figure 1A and 1C).  Further analysis revealed that some of the amino 
acid differences in the rhesus macaque CCL20 protein differ in their hydrophobic or hydrophilic 
nature, highlighted in blue in Figure 1B.  These analyses provided evidence of the differences 
between human and rhesus CCL20 that may cause mis-interpretation of results when using 
human tests (ELISA, Immunoblotting, IHC, and FC) to detect rhesus chemokine.  Specifically, 
antibodies raised against a human antigen may cover a sequence that exhibits amino acid 
differences in the rhesus sequence.  The binding affinity of the antibodies to antigen may be 
reduced by these amino acid changes.  I have observed by ELISA and immunoblotting that the 
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amount of rhesus protein detected by human antibodies and kits was indeed less than the actual 
amount of rhesus protein present (data not shown).  
  
 
 
To generate recombinant macaque chemokines, Origami B DE3 E. coli cells were 
transformed with the p.SUMO.rh.CCL20 plasmid were cultured and protein expression was 
induced with IPTG for 3 hours.  The calculated molecular weight of the SUMO-CCL20 fusion 
Figure 1. Amino acid differences of rhesus macaque CCL20. A. The rhesus macaque CCL20 
gene was sequenced from the SUMO plasmid and the amino acid translation was aligned with 
the human reference sequence using Vector NTI software.  B. Properties of the amino acid 
substitutions were analyzed.      C. Cn3D (v4.1) software was utilized to view the tertiary 
structure of the human CCL20 chemokine.  Orange bars indicate the di-sulfide bonds (Cys6-
Cys32 and Cys7-Cys48).  Yellow highlighted regions are the amino acid residues that differ in 
rhesus macaque CCL20 versus human CCL20.  Copper colored block arrows indicate β-sheets 
and the green colored block cylinder indicates an α-helix secondary protein structure.  
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protein is 26-28kDa based on the addition of the molecular weight of the SUMO tag (~11 kDa, 
although it migrates through a denatured SDS-PAGE matrix to a size range of 18-20kDa 
[Lifesensors]) and CCL20 [8 kDa]).  The darker staining band present only after IPTG induction 
in the molecular weight range between 22 and 36 kDa (lane 4, Figure 2A) indicates that IPTG 
induced a protein of the anticipated size, and is likely the SUMO-CCL20 fusion protein.   
Figure 2. SUMO-CCL20 fusion protein purification and cleavage. A. Origami B DE3 cells  
transformed with p.SUMO.rh.CCL20 were cultured in the presence of IPTG to induce protein 
expression. The SUMO fusion protein was then purified by lysis of the culture and subsequent 
centrifugation of inclusion bodies.  Purified SUMO-CCL20 fusion was obtained by metal 
affinity column purification via the 6X-his tag in SUMO fusion.  Shown is a representative SDS-
PAGE gel of numerous purification protocols. The culture was sampled before and after IPTG 
induction and prepared for SDS-PAGE analysis by boiling at 100°C for 5 minutes with an equal 
volume of 2X SDS-PAGE buffer. Samples taken after IPTG induction were normalized to the 
OD of the before culture to verify the over production of the SUMO fusion protein.  B. Metal 
affinity column purified SUMO-CCL20 fusion protein was dialyzed with 50mM TrisHCl 
500mM NaCl to remove harsh reagents.  The dialyzed protein was cleaved at 37°C with varying 
amounts of SUMO protease as described and aliquots were removed and prepared as above for 
SDS-PAGE analysis in order to analyze the efficiency of cleavage.   All prepared samples were 
separated by electrophoresis on 15% resolving polyacrylamide gel, fixed and stained with 0.25% 
Coomassie brilliant blue.  
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Some inducible or over produced proteins in E. coli aggregate in insoluble inclusion 
bodies (IB)17, 65.  Based on this limitation, further steps need to be taken to purify recombinant 
proteins, if they are insoluble.  To purify the induced protein and determine whether the SUMO–
CCL20 fusion protein was soluble or insoluble, the E. coli culture was pelleted and lysed.  
Centrifugation separated soluble and insoluble material including inclusion bodies.  The 
insoluble pellet was then solubilized with reducing and chaotropic agents to disaggregate protein 
by disrupting and protecting free charged atoms from inter- and intra- molecular bonding.  After 
another round of centrifugation, the supernatant containing solubilized inclusion body proteins 
was analyzed for the presence of the SUMO-CCL20 fusion protein.  The lack of a 26-28kDa 
band present in the soluble fraction after cell lysis, shown in lane 5 [After IB Purification], 
Figure 2A indicated that the induced SUMO-CCL20 fusion protein was located nearly 
exclusively in inclusion bodies.   
The SUMO fusion tag contains a hexahistidine (6X-His) tag that allows the SUMO-
CCL20 fusion protein to be purified from cell lysate via metal affinity column purification, by 
binding to nickel or cobalt ions in the column (Life Sensors).  In lane 6 [Purified SUMO-CCL20 
fusion] Figure 2A, only one protein of size 26-28kDa was abundant, which confirmed that only 
the 6X-His tagged SUMO-CCL20 fusion protein was purified by metal affinity column binding.    
In summary, sequence differences between the human and rhesus CCL20 warrant the 
production of non-human primate chemokines to use as reagents in monkey models studying 
immunology and infectious disease.  The recombinant protein expression system using SUMO 
fusion technology to express rhesus macaque CCL20 in the Origami B DE3 E. coli strain 
produced a protein of the anticipated size of SUMO-CCL20 fusion upon IPTG induction.  The 
induced protein was aggregated in inclusion bodies, but was purified by centrifugation and 
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solubilization.  The solubilized SUMO-CCL20 fusion protein was abundant after metal affinity 
column purification, indicating that a 6X-His tag protein was purified.  The success of the 
expression and purification of the SUMO-CCL20 fusion means that this system is a good 
candidate protocol for obtaining recombinant SUMO-rhesus chemokines.  
4.1.1 Cleavage of the SUMO-CCL20 fusion protein  
To obtain bioactive chemokine from recombinant protein expression using the SUMO 
fusion technology, the chemokine (CCL20) must likely be cleaved from the fusion protein.  The 
SUMO fusion system is ideal for obtaining recombinant proteins because the SUMO protease 
recognizes only the tertiary structure of the SUMO tag in the protein rather than recognizing 
cryptic or inappropriate target sequences for cleavage.  Additionally, the SUMO protease was 
mutated to contain a 6X His tag and can therefore be removed from preparations via the same 
metal affinity column purification (Talon Spin Columns [Clontech]).  These facts facilitate the 
resultant desired recombinant chemokine from being cleaved inside the protein and that after a 
second round of metal affinity column purification, all that should flow through is the final 
cleaved recombinant chemokine.  
 Depicted in Figure 2B, is the pattern of a typical cleavage reaction with the SUMO-
CCL20 fusion protein.  The same amount of purified SUMO-CCL20 fusion protein was cleaved 
with SUMO protease, 10 or 30 units, and the reaction was incubated for 1.5 hours at 37°C.  The 
appearance of two lower molecular weight proteins in lanes 2 through 5 of Figure 2B showed 
that the SUMO-CCL20 fusion protein was indeed cleaved by the SUMO protease.  Comparison 
of the reduced intensity of staining of the substrate (the largest staining protein band in lanes 2 
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through 5) to the input substrate (lane 1), revealed that after 1 hour, the SUMO protease was only 
able to cleave about 10-30% of the SUMO-CCL20 fusion protein.  Additionally, there appeared 
to be little difference in the efficiency of the cleavage reactions, even upon increasing SUMO 
protease 10-30 times the recommended amount (1U protease cleaves 100µg [Lifesensors]).   
Increasing the time of the reaction by a short time also did not appear to have an effect on 
increasing the efficiency of the cleavage reaction (lanes 3 and 5, Fig. 2B).  
 
Figure 3. SUMO-CCL20 is cleaved inefficiently, although SUMO protease is highly 
efficient at cleaving control SUMO fusions. 150ug/ml of purified SUMO-CCL20 fusion 
protein was cleaved with 10 units of SUMO protease at 30˚C for 1 hour. As a control for 
protease activity, 50ug/ml of SUMO-met-GFP was cleaved with 3 units of protease under the 
same conditions.  Both cleavage reaction samples were then stored at 4˚C overnight to allow 
for complete cleavage of fusion proteins. The first panel shows the MW marker, SUMO 
protease control (26kDa) and synthetic CCL20 (8kDa). Samples were prepared for SDS-PAGE 
analysis by boiling at 100°C for 5 minutes with an equal volume of 2X SDS-PAGE buffer. All 
prepared samples were separated by electrophoresis on 15% resolving polyacrylamide gel, 
fixed and stained with 0.25% Coomassie brilliant blue.  
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One of the first steps taken toward optimizing the cleavage of SUMO-CCL20 fusion was 
to verify the ability of the SUMO protease to cleave SUMO fusions.  To clarify this, the SUMO-
CCL20 fusion and the control SUMO-met-GFP fusion (LifeSensors) were cleaved with SUMO 
protease at 30°C for 1 hour and then at 4°C overnight.   The second panel of Figure 3 confirms in 
an independent experiment, as previously described in Figure 2B, there was inefficient cleavage 
of the SUMO-CCL20 fusion.  Cleavage of the SUMO-CCL20 fusion was not completed even 
with overnight incubation with SUMO protease.  However, the control fusion SUMO-met-GFP 
was cleaved nearly completely after only one hour, which verified that the SUMO protease was 
active and efficient.  Complete cleavage of the control SUMO fusion protein was achieved with 
incubation overnight, proving that as described by the manufacturer, SUMO protease is also 
active at 4°C. 
  Since there appeared to be problems with cleavage of the SUMO-CCL20 fusion protein 
(Figure 2B and 3), it was decided that a strategy to improve cleavage efficiency was necessary.  
Development of a multi-parameter experiment may solve the problem of identifying optimal 
cleavage conditions.  In the next section, I will describe my efforts at increasing the efficiency of 
cleavage of the SUMO-CCL20 fusion. 
4.2 Strategies to increase efficiency of cleavage 
After demonstrating that the SUMO protease was active (Figure 3) and that the SUMO-
CCL20 fusion protein was not efficiently cleaved (Figure 2B and Figure 3), I reasoned that there 
were many possibilities for observing inefficient cleavage of the SUMO-CCL20 fusion protein.  
I developed a multi-parameter experiment to optimize the efficiency of cleavage of the SUMO-
CCL20 fusion.   
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4.2.1 Multi-parameter cleavage experimental design  
Optimization of the cleavage reaction was required for obtaining cleaved recombinant 
chemokine prior to HPLC purification and use in bioassays.  A multi-parameter experiment was 
performed with the goal of increasing efficiency of cleavage of the SUMO-CCL20 fusion.  To 
work towards identifying parameters that would increase cleavage of the SUMO-CCL20 fusion, 
the parameters analyzed were the use of differing dialysis buffers, refolding techniques and 
temperature or concentration dependent variables.  The specific parameters analyzed were the 
time at which the protein was refolded, the dialysis reagents and concentrations of cleavage 
reaction reagents and the temperature at which the cleavage reaction was performed.  A flow 
chart, shown in Figure 4, depicts the variables analyzed in the multi-parameter experiment.     
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Figure 4. Multi-parameter cleavage analysis. Optimal conditions for cleavage of the SUMO-
CCL20 fusion protein were analyzed in a multi-parameter experiment.  Metal affinity column 
purified SUMO-CCL20 fusion protein was dialyzed against solutions containing 20mM Tris 
HCl/150mM NaCl or 50mM Tris HCl/500mM NaCl.  Fusion proteins collected after dialysis in 
either solution were then separated again based upon whether or not the protein existed in the 
nascent form (not refolded) or in a chemically refolded state (refolded).  Each of the samples was 
quantified by BCA protein assay.  Fusion proteins were resuspended at the concentrations shown 
above (50, 100 and 200µg/ml).  Cleavage was then carried out using 1, 2, or 3 units of protease 
at the above temperatures (30°C and 37°C).   
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4.2.1.1 Differences in buffer, quantity of protease or protein, time and temperature do not 
increase the efficiency of cleavage of SUMO-CCL20.   
To analyze the effects of varied conditions of the multi-parameter optimization 
experiment, SUMO-CCL20 fusion protein was dialyzed against one of two different neutral salt 
buffers.  The protein was then placed under conditions thought to facilitate refolding or allowed 
to remain in the form after dialysis.  Cleavage reactions containing differing amounts of substrate 
ranging from 50-200µg/ml were carried out at different temperatures with different amounts of 
protease.  SDS-PAGE with Coomassie brilliant blue staining was performed to analyze the 
results of the different cleavage reactions.    
To analyze the difference in dialysis buffers on the cleavage of not-refolded SUMO-
CCL20 fusion, different amounts of protease were added to varying amounts of SUMO-CCL20 
fusion.  The cleavage reaction was incubated at either 30°C or 37°C for 1 (1h) or 2 hours (2h) to 
identify possible temperature or time dependent differences in efficiency of cleavage.  In 
contrary to the manufacturer’s reference that one unit of SUMO protease cleaves 100µg of 
SUMO fusion protein (Lifesensors); all gels shown below in Figure 5 revealed that none of the 
conditions examined lead to efficient cleavage of the SUMO-CCL20 fusion.   
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 Under the conditions analyzed, where 3U (or 3 units of SUMO protease) was the largest 
amount of protease added to the cleavage reaction, and 50µg  (2.5µg) total SUMO-CCL20 fusion 
was the least amount of substrate added to the cleavage reaction, increasing the amount of 
protease did not increase the extent of cleavage the SUMO-CCL20 fusion protein, first gel panel, 
Figure 5.  Additionally, the middle panel and far right panel of the lower gel, where 3 units of 
protease was used to cleave 100µg (5µg) of SUMO-CCL20 fusion revealed that increasing the 
amount of protease did not increase the efficiency of cleavage.  All other gel panels lend 
additional support to the overall conclusion of increasing the amount of protease does not 
increase the efficiency of cleavage by a significant degree.    
Comparison of the top and bottom 2 right gels (1U, 5µg, 30ºC and 37ºC with dialysis 
buffer containing 50mM TrisHCl and 3U, 5µg, 30ºC and 37ºC with dialysis buffer containing 
20mM TrisHCl) indicates that temperatures of  30°C vs. 37°C yielded similar, incomplete levels 
of cleavage.  Based on the decreased intensity of staining of the SUMO-CCL20 fusion protein 
(lane T0h of each gel) compared to the staining in lane T1h of each gel and also given the 
appearance of 3 smaller proteins (2 bands at ~22kDa and 1 very light band at ~8kDa), the 
percentage of SUMO-CCL20 fusion that was cleaved was about 20-30%.  Additionally, there 
was little to no increased detection of cleavage products after another hour of cleavage (lane T2h 
of each gel).   
Figure 5. Changing four different variables did not increase cleavage efficiency of the 'not 
refolded' SUMO-CCL20 fusion.  SUMO-CCL20 fusion protein was quantified by BCA assay 
to achieve the final concentrations in the cleavage reaction as shown.  Metal affinity column 
purified SUMO-CCL20 fusion protein that was not chemically refolded prior to cleavage was 
aliquotted into 50µg/ml (2.5μg), 100µg/ml (5μg), 200µg/ml (10μg) total protein concentrations, 
cleaved with varying quantities of SUMO protease and the reaction was allowed to continue for 
1 hour at either 30° or 37°C.  Samples were prepared for SDS-PAGE analysis by boiling at 
100°C for 5 minutes with an equal volume of 2X SDS-PAGE buffer.  All prepared samples were 
separated by electrophoresis on 15% resolving polyacrylamide gel, fixed and stained with 0.25% 
Coomassie brilliant blue.   
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In summary, the multi-parameter experiment showed that the SUMO protease did cleave 
the SUMO-CCL20 fusion.  However, the cleavage of the SUMO-CCL20 fusion protein was not 
efficient.  The composition of the dialysis buffer in which the protein was equilibrated did not 
appear to have a significant effect on the efficiency of cleavage.  Therefore, it was decided that 
the 50mM TrisHCl dialysis buffer would be sufficient to use in the protocol.  Neither 
temperature analyzed (30ºC or 37ºC) provided any improved cleavage.  No ratio of substrate to 
protease yielded better cleavage than the others, however, based on data from the multi-
parameter experiment, Figures 2B and 3,  as well as additional references70, 71, 73, it was decided 
that a more concentrated substrate provide additional opportunity for diagnosing the efficiency of 
a cleavage reaction.  Overall, the multi-parameter experiment was useful in narrowing down the 
variables to analyze to increase efficiency of cleavage of the SUMO-CCL20 fusion.  
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A broader range of temperatures and incubation periods were then examined, as 
enzymatic activity of SUMO protease was evidenced at a wide range of temperatures 
(Lifesensors).  As shown in Figure 6, the same quantity of refolded or not-refolded SUMO-
CCL20 fusion was cleaved with 10 units SUMO protease at 4°C, 25°C and 37°C.  Samples were 
collected after 3 and 6 hours of incubation and analyzed by SDS-PAGE and Coomassie brilliant 
blue staining, as previously described.   
 Neither temperature nor longer incubation appeared to have an effect on increasing the 
efficiency of cleavage.  Comparing only the top 3 gels, based upon the reduced intensity of the 
Figure 6. Varying temperature and incubation time did not increase the efficiency of 
cleavage of SUMO-CCL20 fusion. Metal affinity column purified SUMO-CCL20 fusion 
protein that was either refolded or not refolded prior to cleavage was cleaved with SUMO 
protease and the reaction was allowed to continue for 3 or 6 hours at 4°, 25° or 37°C.  Samples 
were separated by electrophoresis on 15% resolving polyacrylamide gel, fixed and stained with 
0.25% Coomassie brilliant blue. 
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un-cleaved SUMO-CCL20 fusion protein between 22-36kDa and the appearance of staining of 
products of the cleavage reaction, bands staining between 16-22kDa (SUMO fusion tag) and 
only slightly visible band at ~8kDa (CCL20), efficiency of cleavage was approximately 30% at  
most.  The additional three hours of incubation did not increase cleavage, as seen by the band 
pattern in lane '6hr' in each of the same three top gels.  The same conclusion can be drawn by 
results shown in the bottom 3 gels.  
 There does not appear to be a difference in cleavage of either the chemically refolded or 
not-refolded SUMO-CCL20 fusion, since the ratios of input substrate to products are all about 
the same or a significant amount of SUMO-CCL20 fusion protein appears to be left un-cleaved 
after the endpoint of the reaction.   
 Based on the continued findings of inefficient cleavage, it was possible that something 
inherent to the SUMO-CCL20 fusion prevented it from being cleaved by SUMO protease.  It 
was then hypothesized based on a study done by Calderone, et al, that because the CCL20 
sequence is mammalian there may be mis-incorporated amino acids that could affect the tertiary 
structure of the resultant protein5, which could potentially affecting the ability of the SUMO 
protease to cleave the SUMO-CCL20 fusion protein.   
 Two approaches were utilized to address these questions.  First, a SUMO fusion protein 
that previously had been successfully cleaved in our laboratory, SUMO-CXCL11, was analyzed 
for the capacity of the SUMO protease to cleave that fusion protein.  It does appear that SUMO-
CXCL11 was cleaved more efficiently (data not shown).  This, as well as the success of previous 
experiments by others that showed almost complete cleavage of the SUMO-CXCL11 fusion 
protein (data not shown, Yu-jen Tung), suggests that the specific chemokine attached to the 
SUMO fusion tag affects the efficiency of cleavage.  The efficient cleavage of the SUMO-
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CXCL11 fusion protein suggests that the cleavage of SUMO fusions may be better suited for 
some SUMO chemokine fusion proteins and not others.  
 The method utilized to resolve the other postulate that due to the expression of the fusion 
protein in E. coli there may be mis-incorporated amino acids conferring a different tertiary 
structure that prohibits the SUMO protease from cleaving the fusion protein was the use of 
another strain of E. coli (Rosettagami B DE3). This was done to examine whether synthesis of 
the protein in this strain, which has been modified to express mammalian tRNAs rare in E. coli, 
increased the efficiency of cleavage of the SUMO-CCL20 fusion protein.    
4.2.2 Rosettagami and Origami B DE3 strain of E. coli 
Calderone et al5. showed that E. coli used to express fusion proteins off mammalian 
cDNA sequences could mis-incorporate a lysine residue for an arginine residue, when arginine is 
coded for by ‘AGA’ 5.  Rhesus CCL20 does not contain any ‘AGA’ codons (data not shown).  
The SUMO fusion tag however, contains four ‘AGA’ codon arginine residues (data not shown).  
As postulated previously, mis-incorporation of lysines for these arginine residues might be a 
factor in the poor efficiency of cleavage.  There may be different intramolecular interactions due 
to the amino acid substitution that would affect the structure of the fusion protein causing the 
SUMO protease to be unable to recognize and cleave the fusion protein appropriately.   
To address this we utilized the Rosettagami B DE3 strain of E. coli because of its 
expression of tRNAs that are rarely seen in E. coli.  The p.SUMO.rh.CCL20 plasmid was 
transformed into Rosettagami B DE3 cells and subsequently sequenced.  Analysis of the 
sequences revealed that the p.SUMO.rh.CCL20 plasmid aligned with the reference rhesus 
CCL20 sequence except for one nucleotide substitution (Figure 7).  There was a non-
synonymous ‘T’ to a ‘G’ nucleotide substitution, causing the cysteine at position 32 to be 
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changed to a tryptophan (see Figure 1A for the reference rhesus CCL20 protein sequence). 
Although the SUMO CCL20 expression plasmid had been isolated and sequenced after passing 
through multiple E. coli strains (DH5 alphas and Origami B DE3) the output sequence had no 
nucleotide substitutions.  We then sub-cloned and sequenced five p.SUMO.rh.CCL20 plasmids 
from the Rosettagami B DE3 strain of E. coli.  Each of the sequences of the five isolates of 
p.SUMO.rh.CCL20 showed the same tryptophan substitution at position 32; leading to a 
conclusion that it was possible that the E. coli strain the plasmid was isolated from was affecting 
the sequence output.   
 
            
Since we had not observed this nucleotide substitution before in other E. coli strains, and 
to analyze whether the two original clones of the p.SUMO.rh.CCL20 plasmids had evidence of 
this same base pair change, all past sequence trace files of the p.SUMO.rh.CCL20 plasmid were 
then analyzed (data not shown).  This revealed that in the clone 1 of p.SUMO.rh.CCL20 plasmid 
used in all protein expression, there were two peaks present at the base pair in question (Figure 
7). Results of double peaks seen in a sequencing trace file could mean at least two things.  It 
Figure 7. Isolation of clones of the plasmids p.SUMO.CCL20.1 and p.SUMO.CCL20.2. The 
p.SUMO.CCL20.1 plasmid preparation was shown to have a mixed population of plasmids, with 
either a ‘T’ or a ‘G’ at the base pair in question.  The p.SUMO.CCL20.2 plasmid preparation did 
not have evidence of a mixed population of plasmids.  
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could mean that the gene that was sequenced and used for cloning had a point mutation or that 
there was a mixed population of plasmids in clone 1 of the p.SUMO.rh.CCL20 plasmid.  The 
other original clone (2) of the p.SUMO.rh.CCL20 plasmid showed no evidence of this ambiguity 
at the base pair in question (Figure 7).   
To identify a sub-clone of the p.SUMO.rh.CCL20 (clone 1) plasmid preparation that did 
not show evidence of two peaks in the sequence trace file. Plasmid p.SUMO.rh.CCL20 (clone 1) 
was re-transformed into the DH5α E. coli strain, and individual colonies were sequenced.  Out of 
the five clones (named simply 1.1, 1.2, 1.3, 1.4. 1.5), only plasmid p.SUMO.rh.CCL20.1.1 was 
revealed to have ambiguity at the base in question (Figure 7 and data not shown).  Five clones 
sequenced from plasmid p.SUMO.rh.CCL20 (original clone 2) all aligned with 100% identity to 
the reference rhesus CCL20 sequence.   
After sequencing of five retransformed clones for original clones 1 and 2 of 
p.SUMO.rh.CCL20, revealed that only one retransformed clone named p. SUMO.CCL20.1.1 
showed the base-pair change which translated to a tryptophan substitution at position 32 (from 
cysteine) in the protein, it was hypothesized that the translation of  pSUMO.rh.CCL20.1.1 C32 to 
T32  might be the fusion protein left uncleaved. To address this hypothesis, it was assumed that it 
would be possible to see differences in the cleavage of the sub-clones that translated either 
SUMO-CCL20 fusion with the cognate cysteine32 or mutated tryptophan32. 
4.2.2.1 Differences in SUMO-CCL20 sequence at position 32 do not affect Origami B DE3 
expression or cleavage of protein. 
Because of the differences in the rhesus macaque CCL20 sequence in the plasmid that 
was used in the protein expression system, we sought to determine if these sequence differences 
had an effect on the efficiency of the cleavage of the SUMO-CCL20 protein.  Three different 
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sub-clones of the SUMO-CCL20 fusion protein were sequence verified and transformed into the 
Origami B DE3 E. coli strain.  Protein was induced with the addition of IPTG; the protein was 
purified from the inclusion bodies by centrifugation and metal affinity column purification, as 
previously described.  Purified protein was normalized to total protein concentration and cleaved 
with SUMO protease. There were few differences in the amounts of protein purified (data not 
shown).  As shown in Figure 8, cleavage of the purified SUMO-CCL20 fusion protein was 
inefficient (Figure 8).  Only 25-50% cleavage of the SUMO-CCL20 fusion protein was achieved, 
as depicted by the reduced staining of the SUMO-fusion protein and the appearance of staining 
of two bands lower in molecular weight.  With cleavage of the SUMO-CCL20 fusion protein, the 
SUMO fusion tag of the protein stains in the area of about 22kDa, and rhesus CCL20 stains in 
the area of 8kDa.  The low molecular weight protein marker of synthetic rhesus CCL20 shown in 
lane 2 (CCL20 (8kDa)) confirms that upon cleavage of the SUMO-CCL20 fusion protein a 
protein of similar molecular weight appears and is assumed to be the recombinant CCL20.  
Differences in cleavage of the retransformed SUMO-CCL20 fusion proteins could not be 
attributed to a reduced activity of the SUMO protease as the protease was added at the same time 
in each reaction and the control fusion protein, SUMO-met-GFP, was cleaved within one hour 
(Figure 9, SUMO-met-GFP cleavage).   
 39 
 
 
 
4.2.2.2 Expression and purification of SUMO-CCL20 isolates are different in Rosettagami 
B DE3 cells. 
In the same way as with the Origami B DE3 strain of E. coli, a different strain of E. coli, 
Rosettagami B DE3, was analyzed for differences in efficiency of cleavage of the three different 
p.SUMO.rh.CCL20 retransformed plasmids (sequences shown in Figure 7).  Although the 
purified SUMO-CCL20 fusions were normalized with respect to the total concentration of 
protein, there are apparent differences in the intensity of staining of the protein at the size of the 
anticipated SUMO-CCL20 fusion (22-36kDa, T0, Figure 9).  As shown in Figure 9, there were 
differences in the purity in total protein purified via the metal affinity column purification when 
comparing the banding patterns in the molecular weight range of 22-36 kDa.  The protein 
Figure 8. There is no difference in the expression or cleavage of different isolates of SUMO-
CCL20 fusions purified from the Origami B DE3 strain of E. coli. Recombinant protein 
expression was performed for each of 3 different cultures of transformed Origami B DE3 
sequences that conferred both non-synonymous base pair mutations and reference rhesus CCL20 
sequences with different isolates of the SUMO-CCL20 fusion plasmid.  SUMO-CCL20 fusion 
proteins were cleaved with SUMO protease.  Samples from different conditions were separated 
by electrophoresis on 15% resolving polyacrylamide gel, fixed and stained with 0.25% 
Coomassie blue staining.  
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induced by the retransformed clone of p.SUMO.rh.CCL20 2.2 was more abundant and cleavage 
of this protein was more efficient, as indicated by the reduced staining of the top most band 
(between 22 and 36 kDa) and the appearance of bands staining in the molecular weight range of 
about 22kDa (SUMO-fusion tag) and 8kDa (recombinant rhesus macaque CCL20).  Cleavage of 
the SUMO-CCL20.2.2 from the Rosettagami B DE3 E. coli strain appeared to be similar in 
efficiency to the cleavage observed for the SUMO-CCL20 fusion produced in the Origami B 
DE3 E. coli strain, (Figure 9).  This suggests cleavage of SUMO-CCL20 fusions containing 
wild-type rhesus CCL20 sequence does not differ depending on the strain of E. coli utilized to 
express the fusion protein.  Additionally, there was no increase in cleavage efficiency in using a 
different strain of E. coli, Rosettagami B DE3 for expression of the SUMO-CCL20 fusion. 
 
 
Figure 9. Rosettagami B DE3 cells appear to differ in the expression and cleavage of 
different isolates of SUMO-CCL20 fusions. Recombinant protein expression was performed 
for each of 3 different cultures of transformed Rosettagami B DE3 SUMO-CCL20 fusion 
proteins with sequences that conferred both non-synonymous base pair mutations and reference 
rhesus CCL20 sequences.  SUMO-CCL20 fusion proteins were cleaved with SUMO protease.  
Samples from different conditions were separated by electrophoresis on 15% resolving 
polyacrylamide gel, fixed and stained with 0.25% Coomassie brilliant blue.  
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4.3 Peptide synthesis 
As there were continued problems with obtaining recombinant protein for HPLC 
purification and subsequent biological activity testing, rhesus macaque CCL20 was synthesized 
using regioselective cyclization.  Mature signal peptide cleaved (amino acids 1-70, Figure 1A) 
rhesus macaque CCL20 sequence was forwarded to the University of Pittsburgh Peptide Facility.  
The peptide was synthesized using solid phase peptide synthesis with regioselective cyclization, 
where a peptide is synthesized from the c-terminal amino acid up to the n-terminal amino acid, 
with thiol groups protecting side groups of cysteines to prevent disulfide bond formation, 
intermediately. When the second cysteine amino acid of a disulfide bond is added to the growing 
peptide, the cysteines are de-protected and allowed to form the intended disulfide bond.  For 
CCL20, disulfide bonds are formed between Cys6-Cys32 and Cys7-Cys48.  CCL20 was then 
purified by HPLC and analyzed with NMR.  Pure lyophilized peptide was resuspended in 
nuclease free water and quantitated by BCA protein assay.  This protein was then used in the 
second aim of this study to analyze the CCL20/CCR6 interaction. 
4.4 Overall Protein Expression System Summary 
SUMO-CCL20 fusion was expressed upon IPTG addition and was found to be 
aggregated in inclusion bodies.  The protein was purified and detected by the 6X His-tag in the   
SUMO-tag.  Only 30-50% efficiency of cleavage of the SUMO-CCL20 fusion was achieved 
overall.  Chemically refolding or not refolding in different dialysis buffers did not increase 
efficiency of cleavage.  Varying temperature and changing the ratios of SUMO-CCL20 fusion: 
SUMO protease did not increase efficiency of cleavage.  There was no difference in the cleavage 
of the SUMO-CCL20 in two different E. coli strains, Origami B DE3 or Rosettagami B DE3s.  
Repeated purifications of SUMO-CCL20 fusion from up to 12 L of culture did not yield enough 
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SUMO-CCL20 fusion or cleaved recombinant rhesus CCL20 for bioactivity testing.   To 
generate non-human primate chemokine, rhesus CCL20 was synthesized with regioselective 
cyclization by Univ. Pitt. Peptide Facility for bioactivity testing. 
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5.0  Results: Application of a Functional Chemotaxis Assay to Develop for Vitro System 
Development 
 For the generation of non-human primate chemokines to be useful, the purified resultant 
protein must be proven bioactive in vitro.  To find out whether the nonhuman primate CCL20 
preparation that I had chemically synthesized was bioactive, a cell population that responds to 
the CCL20 had to be identified or developed for testing this factor. 
5.1 Primary Cells 
 With the goal of identifying primary cell populations that express CCR6 and could serve 
as responder cells in CCL20 chemotaxis assay, uninfected primary macaque PBMCs were 
stained with antibodies and flow cytometry was utilized to analyze the expression of CCR6.  As 
shown in Figure 10, a low percentage of cells expressed CCR6.   Only 2% of the total CD3+ 
lymphocyte population expressed CCR6, whereas only 0.7% of CD3- lymphocyte population 
expressed CCR6.  Of the T cells (CD3+) 61% of CD4+ T cells expressed CCR6, and 24% of 
CD8+ T cells expressed CCR6. A large percentage (80%) of B cells, which are CD3- and 
CD20+, expressed CCR6.   
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To determine whether uninfected primary PBMCs would be a good population of cells to 
test the bioactivity of the regioselectively cyclized rhesus macaque CCL20 (abbreviated 
synthetic rhesus CCL20), the isolated PBMCs were placed in a functional chemotaxis assay.  To 
determine whether the small population of PBMCs that express CCR6 (see Figure 10) were able 
to migrate toward to the synthetic rhesus CCL20, freshly isolated normal rhesus PBMCs were 
placed in a chemotaxis assay with a titration of synthetic rhesus CCL20, as well as 2 other 
chemokines, CXCL11 and CCL21.  After incubation at 37ºC with 5% CO2 for 1.5 hours, cells 
that had migrated through the membrane toward the chemokine were counted on a 
hemocytometer.   
Figure 10. CCR6 is expressed on both B- and T-lymphocytes. Flow cytometry was utilized to 
analyze the expression of CCR6 on B and T cells by isolating primary rhesus macaque PBMCs.  
PBMCs were then stained with a 6 color panel (Anti-CD3 Pe-Cy7, Anti-CD4 PerCP, Anti-CD20 
FITC, Anti-CCR6 PE, Anti-CD8 APC-Cy7 and Anti-CD69 APC).  Data was aqcuired on the BD 
Canto, and analyzed with Flow Jo software.   
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 As shown in Figure 11, the cells were able to migrate towards certain chemokines, 
CXCL11 and CCL21, with the highest number of cells migrating towards CCL21.  These results 
are consistent with expression (data not shown), in that, 60-80% of lymphocytes express CCR7, 
the receptor for CCL21, and 30-60% of lymphocytes express CXCR3, the receptor for CXCL11.   
No cells migrated towards the increasing concentrations of CCL20 (Figure 11), suggesting that 
either the synthetic rhesus CCL20 was not bioactive, or the receptor, although expressed, was 
biologically inactive, or that the population tested did not have sufficient numbers of cells that 
expressed CCR6.  
 Given the finding that primary PBMCs do not migrate towards CCL20 despite expression 
of the receptor on both T- and B-lymphocytes, a cell line that expressed CCR6 had to be 
developed to test whether the rhesus macaque CCL20 produced the regioselectively cyclized 
synthesis was bioactive.  The cell line should be one that proliferates quickly, are easily 
Figure 11. Normal macaque PBMCs do not respond to synthetic macaque CCL20.  Freshly 
isolated normal rhesus macaque PBMCs were placed in a chemotaxis assay.  A titration of 
synthetic rhesus macaque CCL20 was prepared in chemotaxis media.  Human CXCL11 and 
CCL21 were prepared in the same manner and used as positive controls for migration.  200,000 
cells (PBMCs) were loaded on the top of the membrane, and the plate was incubated for 1.5 
hours at 37°C and 5% CO2.   
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transfectible and do not respond to many human chemokine receptor ligands, including CCL20.  
Murine L1.2 pre-B cells were found to be a cell line that possessed these properties and were 
therefore utilized in developing a CCR6 cell line63.   
5.2 Regioselectively cyclized synthetic rhesus CCL20 is highly bioactive  
 As there were continued problems with obtaining recombinant chemokine for in vitro 
study, rhesus macaque CCL20 was synthesized by regioselective cyclization, described in 
material and methods and above (section 4.3).  To examine the bioactivity of rhesus macaque 
CCL20 synthesized by regioselectively cyclization, L1.2 murine pre-B cells were transfected 
with a mammalian expression vector, pcDNA3.1 containing the cDNA sequence for human 
CCR6.  After transfection, the cultures were treated with 5mM sodium butyrate overnight to 
increase expression of the receptor.  To determine the expression profiles, cells were then 
isolated, washed and stained with CCR6-specific antibody.  Data were acquired with either the 
Coulter XL or the BD Canto flow cytometers.  CCR6 expression data were further analyzed with 
FlowJo software.  To determine the functionality of the CCR6 receptor in transiently tranfected 
L1.2 cells, the cells were also placed in a traditional chemotaxis assay.  A titration of both human 
and synthetic rhesus macaque CCL20 was prepared was and after three hours incubation at 37°C 
in 5% CO2, cells that had migrated into the bottom well were then counted on a hemocytometer 
and total migrated cells was calculated.   
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 As shown in Figure 12, the transiently transfected cells migrated towards both human and 
synthetic CCL20, demonstrating that in vitro synthetic rhesus CCL20 was bioactive.  Parental 
(untransfected) and mock transfected L1.2 cells did not migrate towards human or synthetic 
rhesus CCL20, indicating that migration was driven by CCR6 (data not shown).  In addition, the 
cells did not migrate towards a non-cognate ligand (CXCL11) or the media only control, 
demonstrating that the migration was specific and CCL20-mediated.  The highest number of 
cells migrated towards 10nM synthetic rhesus CCL20.  It appeared from the dose titration curve 
observed for synthetic rhesus CCL20, that the synthetic rhesus CCL20 was bioactive at a lower 
Figure 12. Peak migration of transiently transfected L1.2 cells is towards 10nM synthetic 
macaque CCL20. Murine L1.2 pre-B cells were transiently transfected with mammalian 
expression vector containing human CCR6 and placed in a chemotaxis assay.  A titration of 
regioselectively cyclized rhesus macaque CCL20 (white bars) and human recombinant CCL20 
(Peprotech) (grey bars) was diluted with chemotaxis media at the concentrations depicted.  
Chemotactic responsiveness was measured by counting cells in the bottom well after a three hour 
incubation at 37°C in 5%CO2.  Data represents an experiment performed in triplicate +/- SD. The 
average number of cells migrating to the positive control was 30,000 cells.   
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concentration than the recombinant human CCL20, since a lower concentration induced more 
cells to migrate (compare 10nM of human and synthetic rhesus CCL20).   
5.2.1 Stable Cell Line Development 
 There was variability in the transfection efficiency with the CCR6 expression plasmid, 
with efficiency varying from 8-60% of the input cells (data not shown).  With a transient 
transfection that is not 100% efficient, it is likely not all the cells loaded on the top of the 
membrane in chemotaxis express CCR6 or respond chemotactically to CCL20.  In addition, to 
complete the study of inhibitory compounds on CCL20-mediated-chemotaxis, it is necessary to 
control these other variables (such as transfection efficiency) with a stable cell line so as not to 
attribute inhibition to these other factors. 
 To obtain a more efficient and controlled population of cells to test CCL20-mediated 
chemotaxis and chemotactic inhibition, stable cell lines were developed.  CCR6 transfected L1.2 
cells were cultured for 48 hours at 37°C in 5% CO2  then resuspended with 1mg/ml G418 
(geneticin).  The cells were then aliquotted into a 96-well plate and cultured in the presence of 
G418 until cell foci were apparent, typically 5-7 days.  These primary clones were cultured, 
treated with sodium butyrate and placed in a CCL20-mediated chemotaxis assay to measure their 
chemotactic responses to CCL20.  Reserved cultures of primary clones that migrated in high 
numbers towards synthetic rhesus CCL20 were further cultured, single cell cloned and confirmed 
for CCL20-mediated chemotaxis.  To this end, 12 stable cell clones were identified and moved 
ahead for further characterization and analysis of CCL20-mediated chemotaxis and inhibition 
studies.    
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5.2.2 A new approach for obtaining highly functional CCR6 expressing cells 
 Stable cell clone selection was performed with two criteria in mind, clones that had both 
high receptor expression and high migratory capacity.  Despite these stable clone selection 
criteria, in some chemotaxis assays, only 5-10% of input stable cells migrated towards the 
optimal concentration of synthetic CCL20, despite greater than 90% of the cells demonstrating 
receptor expression as examined by flow cytometry.  Additionally, since these cells were to be 
used to study possible inhibitors of CCL20-mediated chemotaxis, it would be ideal to study 
inhibition of chemotaxis with cells that displayed high efficiency (80-100%) of migration.  To 
increase the percent of stable cells that would migrate, it was postulated that it might be possible 
to use another method to select highly efficient migrating stable cell clones, so-called 
"Chemotactic Selection".  This is based on the idea that stable cell clones that had already been 
selected based on receptor expression and migratory capabilities may not need sodium butyrate 
pre-treatment to upregulate the chemokine receptor to drive migration. 
To this end, three different stable cell clones were pre-treated with sodium butyrate or not 
and were placed in a traditional chemotaxis assay.  As shown in Figure 13, none of the stable 
CCR6 clones showed CCR6 expression without sodium butyrate treatment, whereas with sodium 
butyrate treatment all of the stable clones, detection of CCR6 expression was 85-95%.  
Additionally, the functional capacity of these cells was dependent on sodium butyrate 
pretreatment, where only the pre-treated cells migrated towards the optimal concentration of 
synthetic CCL20 (Figure 13).   
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In summary, a low percentage of uninfected primary macaque PBMCs expressed CCR6 
but did not respond functionally by chemotaxing towards synthetic rhesus CCL20.  Transient 
transfection yielded only 8-60% efficiency as analyzed by flow cytometry, and only 5-20% 
migration of input cells as analyzed by chemotaxis.  Twelve (12) stable cell lines were 
Figure 13. Only pre-treated stable CCR6 L1.2 cells express CCR6 and migrate towards 
synthetic macaque CCL20. Stable CCR6 L1.2 pre-B cells were treated (+) or not (-) with 5mM 
sodium butyrate overnight.  Cells were then stained with anti-human CCR6-PE (BD biosciences) 
and flow cytometry data was acquired on the BD Canto.  Cells were also placed in a chemotaxis 
assay.  Regioselectively cyclized rhesus macaque CCL20 was diluted with chemotaxis media to 
10nM.  Chemotactic responsiveness was measured by counting cells in the bottom well after a 3 
hour incubation at 37°C/5%CO2 and normalized to the positive control (rhesus CCL20).  Data 
represents an experiment performed in triplicate +/- SD.   
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established to increase CCR6 expression and functional response to CCL20.  Even with 85-95% 
CCR6 expression, only 10-40% of input cells migrated towards synthetic rhesus CCL20.  A 
chemotactic selection strategy of the stable cell clones failed to yield 80-100% migration of input 
cells, but revealed that pre-treatment with sodium butyrate was required to observe a positive 
result of CCR6 expression and CCL20-induced migration. 
5.3 Inhibiting the CCL20/CCR6 Interaction 
 Modifying the CCL20/CCR6 may prove to be important in studying mucosal 
immunology, HIV transmission and vaccinology, so it follows that identifying compounds that 
do inhibit CCL20-mediated chemotaxis is important.  To study the effects of a biochemical 
surfactant, anti-inflammatory botanicals, and receptor peptide mimetics on CCL20-mediated 
chemotaxis, the stable cell lines were utilized.   
5.3.1 GML does not inhibit CCL20-mediated chemotaxis 
 GML (glycerol monolaurate) is an FDA approved fatty acid surfactant used recently to 
inhibit SIV replication.  GML has been shown to have anti-microbial and virucidal properties 
without cytotoxic effects on normal macaque vaginal flora 76, 77.  Based on a study showing that 
inhibition of SIV-induced CCL20 up-regulation observed with GML treatment in the female 
macaque vagina 10, we sought to analyze whether CCL20/CCR6 chemokine/chemokine receptor 
pair was affected by GML.  We used cell clones stably expressing CCR6 L1.2 cells to test this.  
GML at increasing concentrations was added to the chemokine, the cells, or both.  Cytotoxicity 
of the cells was tested separately, and 50µg/ml GML was about 30% cytotoxic when mixed with 
the cells (data not shown). 
A significant variability was observed among the triplicate repeated experiments, and 
may have been due to the slight cytotoxic effects of GML observed at higher concentrations. 
 52 
However, as shown in Figure 14, GML had little effect on CCL20-mediated chemotaxis, 
measured by the percent of migration relative to the positive control (CCL20 with no GML).    
The slight inhibition of migration observed when 50µg/ml of GML was present with both the 
cells and the chemokine was not statistically significant.  In conclusion, we determined that 
within the constraints of this chemotaxis assay, there was not a direct effect of GML on the 
CCL20/CCR6 interaction.   
Since GML did not appear to interact with either CCL20 or CCR6 and higher 
concentrations (50µg/ml) induced cytotoxic effects on the cells, further study was performed 
with the goal of identifying an inhibitor of CCL20 or its receptor CCR6.   
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5.3.2 CCR6 receptor peptide mimetics ECL-2 inhibit CCL20-induced migration  
 Our laboratory has shown that the extracellular loops of chemokine receptors, so called 
receptor peptide mimetics or ECL-X, where X refers to the number of the sequential 
extracellular loop, can bind directly to chemokine64 and inhibit chemokine-induced migration. 
The method of using the second extracellular loop to affect outcomes of signaling through 
chemokine receptors has also been used to inhibit HIV entry by using the second extracellular 
loop of CCR5 85.  Interest in this property of the ECL-X was applied here to CCL20-induced 
migration.  To this end, the second extracellular loop, or ECL-2, of CCR6 (R6 ECL-2) was 
synthesized by the University of Pittsburgh Peptide Facility.  Due to the possibility that the 
cognate rhesus R6 ECL-2 CYS (containing a cysteine residue) could form disulfide bridges in 
solution, two other R6 ECL-2s were also synthesized.  Amino acid substitutions for the cysteine 
residue were decided upon based on weight and isoelectric point, striving for comparable 
behaviors in solution and similar overall molecular weights.   To this end, alanine or threonine 
were substituted for the cysteine during peptide synthesis producing R6 ECL-2 ALA and R6 
ECL-2 THR.  A graphic representation of the location of the extracellular loop with respect to 
the structure of a G protein coupled receptor and the location of the amino substitutions used is 
shown in Figure 15.   
Figure 14. GML does not inhibit CCL20-mediated chemotaxis. Stable CCR6 L1.2 cells were 
prepared as for chemotaxis, with overnight pre-treatment with sodium butyrate.  10nM synthetic 
rhesus CCL20 was prepared and increasing concentrations (µg/ml) of GML were added to the 
chemokine or to the cells.  After a three hour incubation at 37°C in 5% CO2, cells that had 
migrated through the membrane were counted on a hemocytometer and percent migration total 
was calculated as the total number of cells that had migrated towards the positive control, 10nM 
CCL20.  Data represents 3 independent repeats, +/- SD.    
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 The R6 ECL-2 receptor peptide mimetics R6 ECL-2 CYS, ALA and THR were analyzed 
for inhibition of CCL20-mediated chemotactic response in a traditional chemotactic inhibition 
assay.  As shown in Figure 16, R6 ECL-2 with the alanine substitution (R6 ECL-2 ALA) 
significantly inhibited CCL20-mediated chemotaxis 15-50% of the migration observed to the 
optimal 10nM rhesus macaque CCL20 at concentrations of 10nM (p<0.01), 1µM (p<0.05), 
10µM (p<0.001) and 100µM (p<0.05).   R6 ECL-2 CYS (100µM) significantly inhibited 
CCL20-mediated chemotaxis to about 50% migration to the optimal 10nM synthetic rhesus 
CCL20 (p<0.01).  Interestingly, 1nM R6 ECL-2 CYS significantly increased CCL20-mediated 
chemotaxis (p<0.05).  Significant chemotactic inhibition was only observed at 100µM of R6 
ECL-2 THR (p<0.01).  None of the concentrations of the receptor peptide mimetics were 
Figure 15. Design of the second extracellular loop of CCR6 (ECL-2). The regions of the 
sequence of the rhesus macaque were referenced and analyzed to identify inter-, intra-, and 
extra-cellular membrane regions.  Three sequences of the second extracellular loop (ECL-2) 
were synthesized with amino acid substitutions in two of the peptides to negate di-sulfide 
bridge formation in solution.   
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cytotoxic (data not shown), so it can be concluded that the inhibition observed was due to an 
interaction of R6 ECL-2 with either CCL20 or CCR6.   
 56 
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5.3.3 Anti-Inflammatory Botanical Inhibitors 
Botanical elements have long been studied for their medicinal and biochemical 
properties.  Our laboratory has recently been interested in a polyphenol compound found in 
green tea, epigallocatechin gallate, EGCG, due to its anti-inflammatory properties52.  
Additionally, our laboratory has observed that low concentrations of EGCG can inhibit 
chemotaxis of CXCR3+ cells 64.  Biacore binding assays revealed that EGCG bound CXCR3 
ligands with high affinity (ref.64 and Qin, et al, in preparation).   Our laboratory has observed 
another anti-inflammatory property of EGCG in a mouse model of asthma, where there were a 
reduced number of T cells and airway inflammation with EGCG treatment (Qin et al, in 
preparation).  For these reasons, EGCG seemed an excellent candidate inhibitor that may affect 
CCL20-mediated chemtoaxis.   
5.3.3.1 EGCG Inhibition of CCL20-mediated Chemotaxis 
To determine whether EGCG inhibited CCL20-mediated chemotaxis as was observed by 
our laboratory for CXCR3 ligands, stable L1.2 human CCR6 cells were placed in a chemotactic 
inhibition assay with increasing concentrations of EGCG.  A significant (10-20%) inhibition of 
CCL20-mediated chemotaxis was observed at concentrations of 1nM and 10µM EGCG (Figure 
18, p<0.01).  At the 100µM EGCG concentration, 75% inhibition was observed (p<0.001). 
EGCG induced inhibition of CCL20 chemotaxis was at a much higher concentration than we 
have previously observed with EGCG inhibited CXCR3 mediated chemotaxis (Tjoeng, 2009).  
Figure 16. R6 ECL-2 (receptor peptide mimetics) inhibit CCL20-induced migration. 
Stable L1.2 human CCR6 cells were placed in a chemotaxis inhibition assay.  10nM synthetic 
rhesus CCL20 served as a positive control for migration and was mixed with 10 fold increasing 
concentrations (range of 1nM to 100µM) of the 3 receptor peptide mimetics, R6 ECL-2 ALA, 
R6 ECL-2 CYS and R6 ECL-2 THR. Data represents 3 repeat experiments +/- SD.  Paired t-
test, * p<0.05, ** p<0.01, *** p<0.001.     
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Given that inhibition was observed at different concentrations of EGCG, this botanical element 
may interact with either CCL20 or CCR6.     
                                
 
5.3.3.2 Gallotannin Inhibition of CCL20-mediated Chemotaxis 
In an extensive study of naturally occurring botanical anti-inflammatory compounds, our 
laboratory has recently identified gallotannin as an inhibitor of CXCR3-mediated chemotaxis 64.   
Gallotannin is a phenolic metabolite (tannin) that occurs naturally in some foods, chick and cow 
peas, mangos and rhubarb, as well as some nuts 29.  Tannins have been associated with 
scavenging of free radicals, and have been associated with interference of both herpes virus and 
HIV 29.  For these reasons, gallotannin was a prime candidate to test whether it displayed CCL20 
inhibitory properties.  
To determine whether gallotannin exhibited the same inhibitory properties as was 
observed for another chemokine/chemokine receptor interaction (CXCR3 controlled 
Figure 17. EGCG inhibits CCL20-mediated migration. Stable L1.2 human CCR6 cells were 
placed in a chemotaxis inhibition assay.  10nM synthetic rhesus CCL20 served as a positive 
control for migration and was mixed with 10 fold increasing concentrations (range of 1nM to 
100µM) of EGCG. Data represents 3 repeat experiments +/- SD.  * p<0.05, ** p<0.01, *** 
p<0.001.     
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chemotaxis); a chemotactic inhibition assay was performed with synthetic rhesus CCL20 and the 
stable CCR6 L1.2 cells.  Significantly, 100% inhibition of CCL20-mediated chemotaxis was 
observed with 100µM gallotannin (Figure 18).  This level of inhibition was observed in the 
absence of any cytotoxic effects (data not shown).  Due to the chemotactic inhibition, it can be 
concluded then that gallotannin had an effect on CCL20-induced chemotaxis.   
                      
 
5.4 Overall Functional Application Summary  
Low CCR6 expression of uninfected primary PBMCs did not translate to functional 
chemotaxis towards synthetic rhesus CCL20.  The synthesized regioselectively cyclized rhesus 
macaque CCL20 was found to be highly bioactive, inducing more CCL20-mediated chemotaxis 
at a lower concentration (10nM) than a commercial control, human CCL20 (100nM).  Stable cell 
lines were produced to test the bioactivity of both the recombinant and synthetic rhesus macaque 
CCL20 and the inhibitory properties of different biochemical elements.  The surfactant 
Figure 18. Gallotannin inhibits CCL20-mediated migration. Stable L1.2 human CCR6 cells 
were placed in a chemotaxis inhibition assay.  10nM synthetic rhesus CCL20 served as a 
positive control for migration and was mixed with 10 fold increasing concentrations (range of 
1nM to 100µM) of EGCG. Data represents 3 repeat experiments +/- SD.   *** p<0.001.     
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compound that has been linked with reduced SIV replication in the macaque vagina10 where 
CCL20 is expressed, GML, was not found to affect migration towards CCL20.  The receptor 
peptide mimetic, R6 ECL-2 peptides, R6 ECL-2 ALA, CYS and THR were all found to inhibit 
CCL20-mediated chemotaxis significantly at a concentration of 100µM.  R6 ECL-2 ALA was 
also found to significantly inhibit CCL20-mediated chemotaxis at 10nM, 1µM and 10µM. n R6 
ECL-2 CYS significantly enhanced CCL20-mediated chemotaxis at 1nM.  The anti-
inflammatory botanical EGCG inhibited chemotaxis at 1nM, 10µM and 100µM, with almost 
complete inhibition observed at 100µM.  Another botanical anti-inflammatory, gallotannin, 
significantly inhibited chemotaxis to 100% at 100µM.  Inhibitory concentrations of all anti-
inflammatory elements that inhibited CCL20-mediated chemotaxis were all higher than has been 
observed previously in our laboratory. 
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6.0  Discussion 
 Chemokines are important factors in immunology in that they exhibit multiple functional 
roles, including lymph organogenesis, polarization of immune responses and leukocyte 
trafficking.  Non-human primate chemokines are unavailable for use in studies modeling 
immunological responses, infectious disease and pathogenesis.  My project provided our 
laboratory with two methods by which to obtain non human primate chemokines to use in vitro 
and in vivo.  Additionally, I improved our understanding of the affect of our repertoire of anti-
inflammatory compounds, in addition to studying new compounds to study (GML), on the 
CCL20/CCR6 interaction.   
6.1 Protein Expression  
Both the Origami B DE3 and Rosettagami B DE3 strains of E. coli were utilized due to 
their ability to over-express proteins via IPTG addition and plasmids encoding a gene that aided 
in the di-sulfide bond formation in the cytosol that may disallow over-expressed proteins to 
aggregate in inclusion bodies.  The SUMO fusion technology was utilized due to the ease of 
purification of the SUMO-fusion proteins and the specificity of the SUMO protease.  I found that 
both strains of E. coli expressed the protein upon IPTG induction.  However, the resultant 
SUMO-CCL20 fusion protein aggregated in inclusion bodies.   
Aggregation may have affected the ability to extract and purify abundant SUMO-CCL20 
fusion proteins as large scale batch (up to 12L) protein expression did not yield sufficiently high 
quantities of SUMO-CCL20 fusion protein, since after HPLC purification of the yield of 1.7 
milligrams of SUMO-CCL20, 10µg of SUMO-CCL20 fusion was available for additional 
cleavage testing and biological activity testing.  Factors affecting the yield of SUMO-CCL20 are 
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potentially that all inter-molecular bonding of aggregated proteins might not be completely 
dispersed and some of this protein may not be a proper substrate for metal affinity column 
purification.  Evidence to this fact is that it has been shown  that once proteins have aggregated 
in proteins, these same proteins could have a tendency to aggregate in solution despite reducing 
and chaotropic agents that should disrupt inter-molecular aggregation.    
Reasons for  the aggregation of SUMO-CCL20 in inclusion bodies are as follows.  It may 
be that SUMO-fusion proteins have a propensity to aggregate upon over-production.  It may also 
be that the sequence and structure of the chemokine-here CCL20-contribute to the formation of 
inclusion bodies.  Disulfide bonding in the cytosol has long been identified as a difficulty in E. 
coli due to the reduced state of the cytosol 75. This may be a reason why inclusion bodies are still 
formed despite the expression of a thioredoxin reductase and glutathione reductase, two factors 
that increase the formation of disulfide bonds in the cytosol 72.  Additionally, it has been shown 
that proteins that are cytotoxic to E. coli are aggregated in inclusion bodies 72, 74. CCL20 has 
been proven to have anti-microbial properties which may contribute to its aggregation in 
inclusion bodies upon overproduction23.  
The SUMO fusion technology was successful in providing relatively low quantities of 
pure protein.  However, when the time came to remove the SUMO-fusion tag by cleavage with 
the SUMO protease, the cleavage of the SUMO-CCL20 fusion protein was only about 30% 
efficient and precluded the ability to obtain enough recombinant protein for bioactivity analysis.   
The main issue with the recombinant protein expression system here was the poor yield 
of the desired, final protein.  Cleavage of the SUMO-CCL20 protein, despite efforts at 
optimizing the yield and cleavage of the protein, remained at an efficiency of only 30-50%.  The 
multi-parameter experiment (Figure 4) did not reveal conditions optimal for cleavage.  None of 
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the reaction conditions showed complete cleavage of the SUMO-CCL20 fusion protein (Figure 5 
and 6), despite the protease being shown to be active (Figure 3).  Use of two different strains of 
E. coli did not change the efficiency of cleavage (Figure 8 and 9).   
It may be that the cleavage site in the SUMO-CCL20 fusion protein is unavailable for the 
protease.  Because the recognition 'site' of the SUMO protease is the tertiary structure of SUMO 
tag, the fusion protein requires refolding through chemical agents and dialysis in a neutral buffer, 
so that both the chemokine and fusion tag of the protein have the best chance to be in the proper 
tertiary structure(s) to allow efficient cleavage.  Refolding of the fusion protein could make the 
cleavage site of the fusion protein unable to be recognized by the SUMO protease, in that the 
tertiary structure of the SUMO-CCL20 fusion would be disrupted as the chemokine may fold 
over the SUMO protease recognition sequence.   Additionally, or even in conjunction, there 
might be different co-existent entities of partially folded fusion proteins, misfolded fusion 
proteins and properly folded fusion proteins that influence the level of cleavage that can be 
detected.  It may be that the SUMO-CCL20 fusion protein that is evidenced as being cleaved 
(Fig 2B and Figure 3) may be only the properly folded fusion protein and other mis-folded 
SUMO-CCL20 fusions are left uncleaved.   
Inefficient cleavage may be the result of SUMO protease may be more active in cleaving 
the SUMO-CCL20 fusion protein at a different concentration or temperature than was examined 
in the multi-parameter analysis.  It may also be that despite using Rosettagami B DE3 cells to 
control the incorporation of rare tRNAs, there were mis-incorporations of amino acids in the 
SUMO tag protein versus mis-incorporation in the rhesus CCL20 protein since, as stated in 
section 4.2.2, SUMO tag contains four 'AGA' targets for mis-incorporation5. Mis-incorporation 
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could again cause disrupted proper tertiary structure of SUMO tag protein hindering its 
recognition by SUMO protease.   
Despite the problems with cleavage of SUMO-CCL20 fusion, a bioactive form of rhesus 
macaque CCL20 was chemically synthesized.  Regioselective cyclization peptide synthesis 
provided a method to obtain a large batch (35mgs) of highly pure protein measured by HPLC.  In 
vitro studies revealed the rhesus macaque CCL20 was highly bioactive.   
The assessment of the recombinant expression protocol utilizing the SUMO technology is 
that further optimization and study may reveal the steps by which large quantities of a 
recombinant rhesus macaque CCL20 can be purified and used in vitro or in vivo as a therapeutic 
agent or vaccine adjuvant.  Although peptide synthesis provided a method by which highly pure 
bioactive protein was produced, mutation or amino acid substitution analysis of the protein 
sequence to identify important binding sequences of recombinant chemokine would be much 
more expensive and therefore limited than utilizing the recombinant expression system.  Both 
recombinant expression and chemical synthesis of a rhesus macaque chemokine is definitely 
needed because very few if any macaque chemokines are available commercially.   
6.2 Application of a functional chemotaxis assay for in vitro system development  
A cell line expressing stable CCR6 was produced to study the bioactivity of both the 
recombinant and synthesized rhesus macaque CCL20.  Enough SUMO-CCL20 fusion or cleaved 
recombinant rhesus CCL20 was not produced, and therefore bioactivity of the recombinant 
proteins was not measured.  Rhesus macaque CCL20 was generated for bioactivity testing by 
peptide synthesis using regioselective cyclization.  The synthetic rhesus macaque CCL20, in 
contrast, was shown to be highly bioactive in a chemotaxis assay.  Multiple compounds were 
analyzed for inhibition of CCL20-mediated chemotaxis.  The biochemical anti-microbial 
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surfactant, GML, did not have a direct effect on CCL20-mediated chemotaxis.  Second 
extracellular receptor peptide mimetics R6 ECL-2 ALA, R6 ECL-2 CYS and R6 ECL-2 THR 
were shown to inhibit chemotaxis at high concentrations and were determined to have some 
effect on CCL20-mediated chemotaxis.  Both anti-inflammaotry botanicals, EGCG and 
Gallotannin, analyzed potently inhibited chemotaxis at high concentrations.   
In vivo studies of the response of immune cells to intradermal injections with synthetic 
rhesus CCL20 did not show that an inflammatory response to the chemokine.  After further 
analysis, it may be that the concentration of CCL20 administered may have been at a 
concentration too high to elicit an appropriate localized immune response.  CCL20 may have 
been marked for degradation due to the over-abundance by the 'chemokine sink' receptors which 
act to sequester over abundant chemokine25.  Another possible explanation is that the time at 
which samples were taken for analysis was too soon to observe the effects of the CCL20 skin 
injections.   
The importance of the development of a cell line stably expressing CCR6 is that the 
specific response to CCL20 and how that response may be affected by potential inhibitors can be 
studied.  For example, on primary cells isolated from the blood or other tissues, there are a 
variety of chemokine receptors expressed on any cell type3.  While the varied chemokine 
expression is no doubt immunologically indispensable, study of the influence of an individual 
chemokine response (i.e. CCL20/CCR6) would be difficult to interpret and define functionally.  
Therefore defining the specific effect of any inhibitory element on the CCL20/CCR6 interaction 
is warranted in chemokine/chemokine receptor in vitro studies.   
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6.3 Conclusion 
In conclusion, the utilization of the recombinant protein expression system to produce 
chemokines can sufficiently produce pure SUMO-CCL20 fusion proteins, but the quantity of 
culture needed to produce enough SUMO-CCL20 fusion or recombinant CCL20 for bioactivity 
testing was not feasible.  Additionally, the most efficient cleavage of the SUMO-CCL20 fusion 
protein achieved was about 30-50% cleavage.   
In addition, the CCR6 stable cell lines were highly efficient at responding to synthetic 
rhesus CCL20 and represents a good tool for performing CCL20 chemotaxis inhibition.  Using 
this assay, I determined that the CCR6/CCL20 interaction was modulated by high concentrations 
of several compounds, R6 ECL-2 peptides and the botanical elements, EGCG and gallotannin.   
The model of chemotactic inhibition induced by EGCG and gallotannin has been 
described elsewhere64.  Briefly, the high number of hydroxyl groups on the gallate groups of 
both EGCG and gallotannin may mimic glycosaminoglycans (GAGs)60 and bind to GAG binding 
domains on the chemokine, in this case, CCL20.  The fact that only high concentrations of both 
botanicals inhibited chemotaxis may mean that gag binding domains within rhesus CCL20 are 
resistant to binding of EGCG or gallotannin gallate groups.   
6.3.1 Next Steps and Future Studies 
In taking these studies to the next level, the following studies will be important to 
execute.  The expression and purification protocol needs further optimization and adaptation to 
be useful for any future in vitro or in vivo studies with recombinant rhesus macaque CCL20.  
Also, the bioactivity of the SUMO-CCL20 and the recombinant CCL20 needs to be tested.  To 
optimize the yield of SUMO-CCL20, the plasmid containing both the fusion protein tag and 
rhesus CCL20 could be codon optimized for E.coli expression.  This may help to determine 
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whether the problems of cleavage could be attributed to the mis-incorporations of amino acids in 
both the SUMO fusion protein tag and rhesus CCL20.  Expression of the protein could be carried 
out at different temperatures to analyze whether the solubility of the fusion protein could be 
increased.  A soluble protein may be cleaved more efficiently and this would increase the yield 
of recombinant rhesus CCL20 from the expression system. 
The stable CCR6 cell line could be utilized to test the effects other anti-inflammatory 
compounds, such as curcumin, other green tea polyphenols, EGC, ECG, and EC, on CCL20-
mediated chemotaxis.  To further confirm the model of inhibition of CCL20-mediated 
chemotaxis via gallate groups acting as GAG binding domains, the GAG binding domain of 
CCL20 could be mutated, as suggested in Tjoeng, 200964.   
In vitro dendritic cell studies could be performed to analyze whether addition of CCL20 
and HIV immunogens would enhance antigen processing and subsequent T cell priming and 
direction in vitro.  Specifically, a prime and boost strategy of vaccination using CCL20 as an 
adjuvant for HIV immunogens could be performed to identify whether CCL20 is in fact a 
candidate adjuvant for vaccine studies.   
Since constitutive CCL20 expression has been shown in the vagina and colon, but likely 
is also present at the anal/rectal junction, and since it has been suggested that chemokine receptor 
expression is or may be involved in the directing of immune cells to different tissue 
environments, it could be tested whether using CCL20 as a vaccine adjuvant also directed 
memory T cells to the correct tissue compartment (i.e. vagina, anal/rectal junction, or colon) for 
fighting initial HIV/SIV challenge.  The synthetic rhesus CCL20 could be used as a vaccine 
adjuvant in mucosal delivery (vaginal or anal/rectal) of highly expressed SIV or HIV 
immunogens to study whether the delivery of CCL20 with SIV/HIV immunogens boosts the 
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initial immune response to sexual transmission of SIV/HIV in that tissue compartment.  
Specifically, another prime and boost vaccination strategy, but where both the immunogen 
(HIV/SIV proteins) and adjuvant (CCL20) were applied to the mucosal interface where initial 
challenge occurs in transmission (vagina, anal/rectal junction, or colon).  If CCL20 were  found 
to be a candidate adjuvant, stronger memory T cell responses would be observed with the use of 
CCL20 and immunogen versus immunogen alone upon HIV/SIV challenge.   
Since inhibition of CCL20-mediated chemotaxis was observed, any one of the 
compounds could be used in vivo to study the effects of the compound on vaginal SIV 
transmission, similar to the study done by Li, et al with GML10.  Specifically, the question would 
be whether the mucosal delivery of anti-inflammatory compounds inhibits SIV/HIV 
transmission.  Although, this may seem contradictory to a desired immunological outcome of a 
fast and strong response to the invading pathogen (HIV), it may be that despite chronic immune 
activation it appears that the virus evades the immune system, turning the favor to a slower 
inflammatory response may give the immune system the foothold it needs to overcome virus 
replication. 
Other immunological diseases that may be studied based on this study are those in which 
at least some of the pathology of the disease is associated with up-regulation of CCL20 
expression.  Examples of diseases to consider with respect to CCL20 expression are chronic 
inflammatory diseases, such as some skin diseases, i.e. atopic dermatitis and psoriasis, or gut 
associated diseases, inflammatory bowel disease (IBD) and Crohn’s disease27 and some 
autoimmune diseases, such as colorectal cancer.  If the up-regulation of CCL20 expression 
causes tissue destruction, application of the anti-inflammatory compounds that inhibited CCL20 
migration may be useful as treatments of these diseases.  For the skin diseases, the inhibitory 
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dose of EGCG or gallotannin could be applied in a cream to psoriatic lesions to test whether the 
treatment reduced the size and longevity (i.e. how long until the lesion disappears) of the lesion.  
Use of the anti-inflammatory compounds for gut associated diseases (IBD, Crohn’s disease) 
would be a little more complicated as the metabolism of EGCG and gallotannin may break down 
or alter the structures (gallate groups) that inhibit CCL20-mediated chemotaxis.  A way in which 
the delivery to more internal tissue compartments of these anti-inflammatory compounds could 
be made easier may be through something like biodegradable microspheres.  Microspheres are 
similar to micelles, in that the desired compound is encased in polylactic acid (PLA)11.  As the 
microsphere degrades, increasing levels of the desired compound are released, in a so-called 
time-release fashion.  Biodegradable microspheres have been used to time deliver insulin in a 
mouse model of diabetes11.  The time-released insulin did appear to aid in leveling the blood 
glucose levels11.  Additionally, while working out their own protocol, the University of 
Pittsburgh Peptide Facility (UPPF) encased our rhesus macaque CCL20 in PLA microspheres.  
Although the protocol was not optimized by UPPF, this at least gives a possible avenue for 
studying the time-release drug delivery hypothesis for anti-inflammatory botanicals.  In the same 
fashion, biodegradable microspheres could be utilized to deliver EGCG or gallotannin to the gut 
essentially unperturbed by metabolic and enzymatic processing or breakdown.  It could then be 
analyzed whether these treatments produced desirable prognosis or outcomes of the disease, i.e. 
reduction of the chronic inflammation of the gut in IBD or Crohn’s disease. 
6.3.2 Public Health Revelance of this Study   
The public health relevance of studying ways to produce recombinant bioactive non-
human primate chemokines is that studies of human immunity and treatment for diseases are 
sometimes modeled in monkeys.  In monkey models of infections and immunologic diseases, 
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most reagents used are of human specificity.  The species difference may alter the immune 
response generated or the ability to detect the antigen, thereby skewing the interpretation of the 
results, which then translate to poor modeling of human immunity and disease.  The use of 
species specific reagents will provide more confidence in the results and interpretations of non-
human primate studies.   
Prevention is a main public health consideration and vaccination is one way prevention of 
transmissible diseases is achieved.  If an anti-inflammatory compound affects the immune 
response to a vaccine, the efficacy and longevity of the vaccine may then be affected.  One 
reason studying how CCL20/CCR6 interaction is modulated by anti-inflammatory compounds is 
that to mount an efficient immune response to vaccinations, a main player is immature DCs 
which express CCR6.  Other factors affecting the efficacy of vaccination are the immunogen and 
the inflammatory immune response that is mounted to a vaccination.  Therefore, identifying anti-
inflammatory compounds that potentially cause a stinted inflammatory response to the vaccine 
and inhibit the influx of CCR6+ immature DCs is important in developing efficacious vaccines.   
An additional reason studying the CCR6/CCL20 interaction is important to public health 
is in relation to the HIV epidemic.  The ultimate goal to eradicate the world-wide HIV-1 
epidemic will require a vaccine to or treatment of HIV that either prevents HIV transmission, or 
cures the prolonged immune activation and also inhibits virus replication.  Recent HIV studies 
have linked CCR6 and CCL20 with both enhanced and reduced HIV replication49, 51, 53, 54, 55 .  
The simple fact that a chemokine/chemokine receptor pair has potentially host-beneficial 
properties is reason to consider the pair in transmission and treatment of HIV.  The 
CCR6/CCL20 interaction may be important in developing ‘a site of entry’ mucosal vaccine to 
HIV because of CCL20 expression in the mucosal tissues involved by sexual transmission of 
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HIV and CCL20’s role in maintaining and recruiting immature DCs within the tissue.  Another 
indication that CCR6/CCL20 should be considered to combat HIV transmission and replication 
is that a naturally occurring anti-HIV molecule, APOBEC3G, is up-regulated by CCR6 
signaling, thereby protecting the cell expressing APOBEC3G from HIV replication49.  These 
findings indicate that CCR6/CCL20 may be important in combating HIV transmission and 
persistence, and therefore important to consider in developing methods to treat and prevent HIV.   
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